VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 23 (13-21 octubre/2025)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Noticias en la Web

Brazil opens world's largest mosquito biofactory to fight disease

Oct 13. The world's largest factory that produces mosquitoes that can prevent dengue, Zika and chikungunya viruses from reproducing has opened in Curitiba, Brazil, aiming to boost protection in 40 municipalities with high infection rates.

The mosquitos, which are infused with the Wolbachia bacterium, prevents viruses carried by the Aedes aegypti mosquito from reproducing, sharply reducing the insect's ability to transmit diseases.

The factory, built by the Oswaldo Cruz Foundation in partnership with the World Mosquito Program and supported by Brazil's Health Ministry, can produce 100 million eggs per week.

The new complex, covering 37,674 square feet, represents an investment of more than $15 million and is expected to benefit about 140 million people.

Employees work in a laboratory of the British biotechnology company Oxitec, in Campinas, Brazil, on October 1. The British biotechnology venture that applies genetic modification to produce Aedes aegypti mosquitoes, whose female offspring are infertile, effectively reducing mosquito populations.

Photo by Isaac Fontana/EPA

"Brazil is now leading this technology worldwide. No other country has such a large public production capacity for mosquitoes with Wolbachia," Health Minister Alexandre Padilha said during the opening ceremony.

The infected mosquitoes are released in urban areas, where they breed with wild populations and pass the bacterium to new generations. Over time, local mosquito populations become naturally "vaccinated," reducing the circulation of arboviruses such as dengue, Zika and chikungunya.

The Wolbachia method was first tested in Brazil more than a decade ago with support from World Mosquito Program and Fiocruz. Early releases showed an average reduction of up to 69% in dengue cases, according to data from pilot projects in Niterói and Rio de Janeiro.

Fiocruz researchers said adult female mosquitoes are fed with artificial blood meals five to six days after emerging, using human blood supplied by the Australian Red Cross or human volunteers, to sustain egg production and survival.

Studies by the World Mosquito Program indicate that egg survival can remain around 50% after overwintering, although high temperatures and low humidity can significantly reduce hatch rates.

"The results are clear: fewer illnesses, fewer hospitalizations and significant savings for the public health system. For every 19 cents invested in Wolbachia, the country saves about $90 in treatments and medication," Fiocruz said in a statement.

Since the method was introduced in 2014, Brazil has become a global leader in using of Wolbachia to control mosquito-borne diseases. The country is now part of a network of 14 nations applying the

technology, including Mexico, Colombia, Indonesia and Australia.

The World Health Organization recognizes Wolbachia as an effective, safe and low-cost tool that complements vaccination and fumigation campaigns.

The Health Ministry said it plans to expand the network of biofactories to reach new regions, including the Northeast and the Amazon, where high temperatures and rainfall favor mosquito breeding.

It is also advancing the domestic production of a dengue vaccine, developed by the Butantan Institute, which aims to manufacture 60 million doses per year starting in 2026.

The Fiocruz-World Mosquito Program biofactory in Curitiba is a public, government-backed project that uses a natural biological method developed in Australia and adapted by Brazilian scientists to introduce the Wolbachia bacterium into mosquito populations.

In contrast, the new Oxitec facility in Campinas, São Paulo, is a private British biotechnology venture that applies genetic modification to produce Aedes aegypti mosquitoes, whose female offspring are infertile, effectively reducing mosquito populations.

The company also breeds mosquitoes carrying the Wolbachia bacterium as part of its combined control strategy. The projects operate independently and are seen as complementary approaches within Brazil's national strategy to control dengue and other mosquito-borne diseases.

"This is a public health policy grounded in Brazilian science, with a direct impact on the lives of millions of people," Padilha said.

Fuente: UPI. Disponible en https://n9.cl/4bkolf

CEPI announces new partnership with Indian vaccine maker

Oct 14. The world's largest vaccine manufacturer, the Serum Institute of India (SII), will partner with CEPI (Coalition for Epidemic Preparedness Innovations) to develop a new vaccine targeting H5N1 avian flu as a prototype for Disease X, an as-yet-unknown pathogen with pandemic potential. The project will be supported by up to $16.4 million.

Smederevac / iStock

The vaccine will be developed on a baculovirus platform and will compare two H5 antigens for a recombinant protein vaccine: a wild-type and an artificial intelligence (AI)-optimized, broad-spectrum H5 antigen designed by scientists at Houston Methodist Research Institute.

> **"This new project—which deepens our collaboration with SII, one of CEPI's preferred vaccine manufacturing partners—is designed to power up global readiness."**

Goal: Produce broad immune response

The goal is to produce a vaccine that elicits a broad immune response across multiple strains of H5 viruses. CEPI said the vaccine is a key part of its 100-day mission of accelerating vaccine development to within 100 days of identifying a pandemic threat.

"This new project—which deepens our collaboration with SII, one of CEPI's preferred vaccine manufacturing partners—is designed to power up global readiness to tackle pandemic threats, from early-stage vaccine development through to global manufacture and supply," said Richard Hatchett, MD, CEO of CEPI, in a press release.

Fuente: CIDRAP University of Minnesota. Disponible en https://n9.cl/drvtji

GSK's RSV Vaccine Study Update: Promising Developments for Older Adults

Oct 15. GlaxoSmithKline (GSK) recently updated its clinical study on the RSVPreF3 OA investigational vaccine, targeting adults aged 60 and older. Officially titled 'A Phase 3, Randomized, Controlled, Partially Blind, Immuno-bridging Study,' the research aims to evaluate the vaccine's immune response, safety, and occurrence of RSV-associated respiratory illnesses. This study is significant as it builds on previous findings demonstrating the vaccine's efficacy against lower respiratory tract disease.

The study tests the RSVPreF3 OA vaccine, a biological intervention administered intramuscularly, designed to prevent respiratory syncytial virus infections. Participants in China and overseas received either the vaccine or a placebo.

The study employs a randomized, parallel intervention model with quadruple masking for Chinese participants, ensuring unbiased results. The primary purpose is prevention, with data collected in an observer-blind manner in China, while overseas participants are part of an open-label study.

Key dates include the study's start on August 9, 2024, and the last update on October 13, 2025. These dates are crucial for tracking progress and ensuring timely data analysis.

This update could positively influence GSK's stock performance by reinforcing investor confidence in the company's vaccine portfolio. As RSV remains a significant health concern, successful results could position GSK favorably against competitors in the vaccine market.

The study is ongoing, with further details available on the ClinicalTrials portal.

Fuente: THE GLOBE AND MAIL. Disponible en https://n9.cl/xrdsh

SK Bioscience Advances Universal Coronavirus Vaccine, Files Global Phase 1/2 Protocol in Australia

Oct 15. SK Bioscience has launched a major effort to develop a universal vaccine that can protect against COVID-19 and other coronaviruses in the same family.

On October 15, the company said it submitted a global Phase 1/2 clinical trial protocol for its vaccine candidate GBP511 to an Australian Human Research Ethics Committee (HREC). GBP511 is designed to target sarbecoviruses, the subgenus that includes SARS and SARS-CoV-2, and is intended to provide cross-protection against existing variants and potential novel coronaviruses.

The planned trial will enroll about 500 healthy adults aged 18 and older in Australia and will assess safety and cross-reactive immune responses, with key readouts expected through 2028.

The GBP511 program began in 2021 during the COVID-19 pandemic through a collaboration between SK Bioscience and the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI provided about $65 million in early R&D funding, covering nonclinical and clinical studies and process development.

A SK Bioscience researcher is conducting analytical experiments for vaccine development. / Courtesy of SK Bioscience

GBP511 builds on the company's recombinant protein-based technology used in Skycovione, South Korea's domestically developed COVID-19 vaccine. The candidate combines SK Bioscience's antigen and recombinant technology with self-assembling nanoparticle design from the University of Washington's Institute for Protein Design. Skycovione previously demonstrated strong immunogenicity and safety in global trials.

While several firms and institutions worldwide are pursuing universal coronavirus vaccines, most remain in early preclinical stages. SK Bioscience's move into a Phase 1/2 clinical trial is considered relatively rapid progress.

The World Health Organization in 2022 identified development of universal sarbecovirus vaccines as a global health priority, citing ongoing viral evolution, waning immunity, reinfection risk, and the potential for animal-to-human transmission. Experts say vaccines that deliver broad cross-protection and long-lasting immunity are essential to prevent future pandemics.

Market research firm Coherent Market Insights projects the global COVID-19 vaccine market will reach roughly $50.6 billion by 2025 and grow at a compound annual rate of 7.4% to about $83.4 billion by 2032, underscoring commercial potential for next-generation solutions like universal vaccines.

SK Bioscience CEO Ahn Jae-yong said, "Although the COVID-19 pandemic has ended, related viruses continue to evolve and threaten humanity. GBP511 is a next-generation vaccine designed to prevent viruses across the family regardless of specific variants, and it will mark a new turning point in pandemic preparedness."

SK Bioscience is also advancing other pandemic-response candidates. In partnership with CEPI, an mRNA Japanese encephalitis vaccine is in global Phase 1/2 trials, and a government-collaborative avian influenza vaccine program began research and development this year.

Fuente: KOREA IT TIMES. Disponible en https://n9.cl/rnnfk

Informe internacional pide una transformación estructural para enfrentar futuras pandemias

Oct 15. Un nuevo informe mundial describe las prioridades de preparación para proteger a las personas en todo el mundo de futuras pandemias y otras crisis sanitarias; pide una mayor inversión en atención primaria de salud, evaluación de riesgos en tiempo real y cooperación internacional para garantizar que las comunidades locales y mundiales estén preparadas para prevenir y responder a la próxima pandemia.

La Junta de Monitoreo de la Preparación Mundial (GPMB, por sus siglas en inglés) publicó su informe de 2025, «El nuevo rostro de la preparación para pandemias», durante la Cumbre Mundial de la Salud celebrada en Berlín. En él se hace un llamado a un cambio transformador en la preparación para pandemias.

El GPMB, establecido en 2018 tras la epidemia de ébola en África Occidental, monitorea el estado de preparación mundial ante pandemias y otras crisis sanitarias. Es una iniciativa apoyada por la Organización Mundial de la Salud y el Banco Mundial.

"En nuestro mundo cada vez más volátil e incierto, la verdadera preparación ante pandemias y otras emergencias sanitarias debe basarse en sistemas de atención primaria de salud eficientes y bien financiados", afirmó Kolinda Grabar-Kitarović, copresidenta del GPMB y expresidenta de Croacia.

> ***"Los sistemas de atención primaria de salud sólidos llegan a las comunidades, prestando servicios de salud esenciales en tiempos de paz y fomentando la confianza profunda, fundamental para una respuesta sanitaria eficaz ante las crisis."***

Cinco años después de la aparición de la COVID-19, el mundo aún lidia con sus consecuencias. Mientras tanto, importantes cambios tecnológicos y geopolíticos presentan tanto oportunidades como desafíos para la seguridad sanitaria mundial. Los avances tecnológicos en el análisis de datos, los medios para desarrollar nuevas vacunas y tratamientos rápidamente, y la adopción de un Acuerdo Generacional contra la Pandemia son avances positivos. Por otro lado, la proliferación de desinformación, la creciente desconfianza y las fuerzas geopolíticas divisivas debilitan la preparación.

> ***"En este contexto, el GPMB en su último informe insta a los gobiernos e instituciones a adoptar un cambio de paradigma para restablecer la arquitectura sanitaria mundial para la preparación ante una pandemia, centrándose en tres acciones: cuidar, medir y cooperar."***

"Las pandemias son choques multidimensionales que exigen respuestas coordinadas y multisectoriales", afirmó Joy Phumaphi, copresidenta del GPMB y exministra de Salud de Botsuana. "Si bien habrá otras pandemias, serán diferentes a las del pasado, y nuestra preparación debe adaptarse a estos cambios. Debemos ir más allá de los esfuerzos fragmentados y adoptar la cooperación y la innovación como pilares de la preparación".

Se necesita un cambio en la "atención" para fortalecer los sistemas de primera línea mediante inversiones en atención primaria de salud, un compromiso más estrecho con las comunidades y una fuerza laboral de salud protegida.

En términos de "medición", el informe pide el establecimiento de un sistema integral de monitoreo del riesgo de pandemia que rastree las amenazas, vulnerabilidades y preparación en tiempo real, integrando datos

sanitarios, sociales, económicos y ambientales en señales claras para los líderes.

En cuanto a la "cooperación", el informe destaca la importancia de una arquitectura sanitaria mundial basada en los principios de solidaridad y equidad, y alienta la ratificación, implementación y financiación del Acuerdo de la OMS sobre Pandemias, con un sistema de Acceso a los Patógenos y Reparto de Beneficios (PABS), junto con la aplicación continua del Reglamento Sanitario Internacional fortalecido, para apoyar el intercambio oportuno y justo de muestras, datos y productos médicos.

2026 será un año crucial para la preparación ante pandemias. El informe de 2025 se basa en el Marco de Monitoreo del GPMB, publicado en 2023 tras dos años de desarrollo y consulta. El marco adopta una perspectiva multisectorial y presenta 90 indicadores agrupados en tres dimensiones: Riesgo; Prevención, Preparación y Resiliencia; e Impacto. El informe de este año se centra en la dimensión de Impacto, destacando la necesidad de realinear los esfuerzos de preparación para afrontar los desafíos futuros.

Junta de Monitoreo de la Preparación Mundial (GPMB)

La Junta de Monitoreo de la Preparación Mundial es un organismo independiente de monitoreo y rendición de cuentas, establecido en 2018 por la OMS y el Banco Mundial para fortalecer la preparación ante crisis sanitarias mundiales. Integrada por líderes políticos, directores de organismos y expertos de renombre mundial, la Junta proporciona evaluaciones independientes y fidedignas del progreso mundial en el desarrollo y mantenimiento de la capacidad para prevenir, detectar y responder a brotes de enfermedades, epidemias, pandemias y otras emergencias sanitaria.

Fuente: La Web de la Salud. Disponible en https://n9.cl/rnlrk

Las vacunas con menor avance en su cobertura mundial

16 oct. A lo largo de las últimas décadas ha existido un crecimiento irregular en la cobertura mundial de algunas vacunas. Aunque lo más preocupante es que a pesar de todos los esfuerzos todavía no se logran los objetivos establecidos por la Organización Mundial de la Salud (OMS).

Por otra parte, otra de las adversidades que han surgido y se han propagado por todo el planeta son los grupos antivacunas. En especial a partir de un falso estudio que asociaba la inmunización con el autismo ahora hay muchas personas que dudan acerca de la utilidad de los biológicos.

¿Cuál es la cobertura ideal de vacunación?

De acuerdo con los estándares de la OMS, la cobertura mundial de las vacunas debe ser igual o mayor a 95% para lograr los objetivos de prevenir epidemias. El problema es que prácticamente ninguna de las inmunizaciones actuales ha logrado dicha cifra a escala global.

¿Para qué funcionan las vacunas?

Generan inmunidad individual. El objetivo principal de una vacuna es “enseñarle” al sistema inmunitario a reconocer y combatir un patógeno específico (virus o bacteria) sin que la persona se enferme.

Generan inmunidad colectiva. Cuando una gran parte de la población está vacunada, se reduce la circulación del patógeno, lo que se conoce como inmunidad de rebaño o colectiva.

Impacto en la salud pública. A nivel global, la vacunación es una de las intervenciones de salud pública más exitosas de la historia porque ha permitido abolir diversas enfermedades.

¿Cuáles son las vacunas con menor crecimiento en su cobertura mundial?

Los datos publicados recientemente por la OMS y el Fondo de las Naciones Unidas para la Infancia (UNICEF) muestran que la cobertura de vacunación infantil se está estancando a nivel global.

Como muestra de lo anterior, tan sólo en el 2024 se reportaron alrededor de 20 millones de niños en todo el mundo no estaban vacunados o lo estaban de forma incompleta.

Además, el número de niños que no recibieron ninguna vacuna alcanzó los 14.3 millones, lo que representa un aumento con respecto de los 12.9 millones que hubo en 2019.

De acuerdo con lo reportado por Statista, el porcentaje de niños que han recibido tres dosis de la vacuna contra la difteria, el tétanos y la tos ferina (DTP), uno de los principales marcadores de la cobertura mundial de inmunización, fue del el 85% en 2024.

Lo anterior es muy grave porque entre el 2016 y 2019 se alcanzó el máximo histórico del 86%, lo que significa que hubo un retroceso global. Los datos también muestran que la tasa de vacunación contra el sarampión se estancó en 76% el año pasado, frente al 86% que se logró en 2019.



Vacunas que sí han crecido en su cobertura mundial

El único punto positivo que se ha logrado durante los últimos años es la introducción de nuevas vacunas y de vacunas infrautilizadas. Algunos ejemplos que vale la pena destacar son las que combaten el Virus del Papiloma Humano (VPH), la meningitis, la infección neumocócica y el rotavirus porque en todos los casos se ha observado un incremento en su cobertura, en especial en los 57 países apoyados por la Alianza Mundial para Vacunas e Inmunización (GAVI).

Fuente: Saludiario. Disponible en https://n9.cl/zq6as

Incluyen en México vacuna Pfizer para campañas de vacunación nacional contra COVID-19

17 oct. La Secretaría de Salud informó que las dosis se aplicarán del 13 de octubre de 2025 al 3 de abril de 2026.

El Gobierno de México contará con la vacuna actualizada de Pfizer para la campaña invernal de inmunización contra la COVID-19.

A través de un comunicado, la farmacéutica detalló que la vacuna está actualizada contra las nuevas variantes de la enfermedad.

Juan Luis Morell, Presidente y Director General de Pfizer México afirmó que se activarán todos los procesos de logística y distribución para que la vacuna actualizada esté a tiempo en los centros de vacunación tanto del sector público como del privado.

Tras el aumento de casos por la nueva variante, Pfizer anunció que pondrá a la venta una nueva vacuna contra la COVID-19 que estará disponible en octubre.

Foto: Galo Cañas Rodríguez / Cuartoscuro.com

"Continuaremos buscando junto con las autoridades sanitarias las vías para que cada vez más personas puedan acceder la vacuna, por ello nos sentimos muy satisfechos con este anuncio de la disponibilidad de la vacuna actualizada en el sector salud," puntualizó.

Gobierno también contará con vacuna de Moderna

La vacuna actualizada contra la COVID-19 de Moderna será incluida en la Campaña Nacional de Vacunación para la temporada invernal 2025–2026.

Moderna informó de la entrega de 4.8 millones de dosis, todas liberadas para su comercialización por la Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).

Fuente: El Sol de México. Disponible en https://goo.su/Ncx4F

EYEGENE launches Phase 2 clinical trials for EG-MCV4, Korea's first homegrown quadrivalent meningococcal vaccine candidate

Oct 17. EYEGENE announced on October 16 the initiation of the domestic Phase 2 clinical trial for 'EG-MCV4 (development code),' a quadrivalent meningococcal vaccine candidate developed with domestic technology.

Prior to this, in July 2024, EYEGENE entered into a 'Meningococcal Quadrivalent Vaccine Development and Exclusive Sales Agreement" with EuBiologics to ensure the successful development and commercialization of EG-MCV4. The company is jointly conducting the development with BMI Korea, which operates a large-scale GMP-certified production facility.

This Phase 2 clinical trial is designed to evaluate the immunogenicity and safety of EG-MCV4 following a single-dose administration in 125 healthy adult participants with no prior history of meningococcal infection. The study will also assess the non-inferiority of EG-MCV4 compared to the reference vaccine, 'Menveo.'

EG-MCV4 has already demonstrated a favorable safety profile in preclinical studies, exhibiting immunogenicity levels comparable to or exceeding those of Menveo across all targeted serotypes (A, C, W-135, and Y). Based on these promising results, EYEGENE intends to proceed with consecutive Phase 2 and Phase 3 clinical trials, with the goal of obtaining product approval in Korea by 2027.

At present, all meningococcal vaccines distributed in Korea are 100% imported. According to data from the Korea Health Industry Development Institute (KHIDI), the domestic meningococcal vaccine market is valued at KRW 10 billion (approximately USD 7 million) annually, with a substantial share of this market comprising government procurement programs for enlisted military personnel.

"The successful development of EG-MCV4 will not only help lower procurement costs by substituting imported vaccines but will also represent a significant milestone toward achieving vaccine self-sufficiency, thereby ensuring a stable vaccine supply in times of infectious disease crises," an EYEGENE official stated.

"EG-MCV4 is Korea's first quadrivalent meningococcal vaccine. We plan to substantially reduce costs compared to imported products in order to compete in the domestic Public Procurement Service bidding market. Additionally, by leveraging our proven domestic technology and strong price competitiveness, we aim to strengthen our position in the global vaccine market," the official further commented.

EYEGENE also intends to pursue rapid expansion into global markets following domestic product approval. According to KHIDI data, the global meningococcal vaccine market is projected to grow at a compound annual growth rate (CAGR) of 9.1%, increasing from USD 3 billion (approximately KRW 4 trillion) in 2021 to USD 5.1 billion by 2027.

The Pan American Health Organization (PAHO), an international body operating under the World Health Organization (WHO), together with UNICEF, constitutes the world's largest vaccine procurement organization. Once product approval in Korea is secured, companies become eligible to participate in PAHO-led tenders without the requirement for separate overseas clinical trials. EYEGENE's strategy plan involves initiating participation in bidding processes across Latin American countries through PAHO, subsequently expanding into the private markets of these regions, and progressively entering key Asian markets, including China, Japan, Thailand, Indonesia, and Malaysia.

EYEGENE Inc.

"EYEGENE CEO Choi Seok-geun, formerly of EuBiologics, successfully entered the international vaccine procurement market by developing the first domestically produced cholera vaccine to obtain WHO prequalification (PQ) approval. His extensive experience and network in global vaccine procurement are expected to greatly strengthen the company's prospects for entry into the PAHO market," an EYEGENE official said.

Fuente: The Bio News. Disponible en https://goo.su/GsIwA6

Recombinant Herpes Zoster Vaccine Is Effective at Reducing Shingles

Oct 18. Researchers from the University of North Carolina at Chapel Hill conducted a study that found two doses of the recombinant herpes zoster vaccine (RZV) are effective at reducing shingles, even for individuals who had previously received the live vaccine (ZVL).

This study, published in the Annals of Internal Medicine on October 14, 2025, concluded that the RZV is effective in older adults, including those who are immunocompromised, and that two doses are more effective than one.

These researchers suggested that prior ZVL recipients should be revaccinated with the RZV.

Vaccine effectiveness (VE) against any herpes zoster (HZ, shingles) outcome was 56.1% (95% CI, 53.1% to 59.0%), with similar VE between immunocompetent (56.5% [CI, 53.2% to 59.5%]) and immunocompromised (54.2% [CI, 44.7% to 62.1%]) individuals.

Individuals vaccinated with ZVL in the past 10 years benefited from RZV.

Furthermore, a second RZV dose conferred an additional 67.9% effectiveness against any HZ outcome.

The RZV was licensed in 2017 by the U.S. FDA, but people with weakened immune systems were excluded from clinical trials. On July 23, 2021, the FDA expanded the indication for RZV to include adults aged ≥18 years who are or will be at increased risk for shingles because of immunodeficiency or immunosuppression caused by known disease or therapy.

Currently, the U.S. CDC recommends RZV over ZVL, which was discontinued in the USA during 2020. the CDC recommends Shingrix® for the prevention of herpes zoster (shingles) and related complications.

As of October 18, 2025, shingles vaccination services are offered at various pharmacies in the USA.

The Primary Funding Source for this study was the National Center for Advancing Translational Sciences.

Fuente: VAX BEFORE TRAVEL. Disponible en https://goo.su/JzkL7a

Pneumococcal Diseases Require Constant Vaccine Development

Oct 19. As *Streptococcus pneumoniae* (*S. pneumoniae*) bacteria evolve over time, vaccine development is forced to follow suit in order to keep patients protected against pneumococcal diseases and their shifting serotypes, according to a session presented at the National Community Pharmacists Association (NCPA) 2025 Annual Convention & Expo.

In her presentation, Jeannie Grubbs, PharmD, manager at Publix Pharmacy, discussed the “shifting epidemiology” of pneumococcal vaccines for adults. She provided the pharmacist audience with insights on available pneumococcal vaccines, recommendations for specific adult populations, and general trends of pneumococcal diseases in the US.

She began her session by exploring the shift in serotype distribution among US patients and how that has caused continuous vaccine development for pneumococcal diseases.

“In 2005, we see this leveling off. What happened? The serotype shift occurred,” said Grubbs. “So now, the 7 [serotypes] that were in that vaccine are not necessarily the serotypes that are protecting the patient population, so we're seeing a leveling off. A new vaccine came on the market, Prevnar 13 [pneumococcal 13-valent conjugate vaccine]. [It] protected against 13 different stereotypes.”

Before diving into the most recent development of pneumococcal conjugate vaccines (PCVs), Grubbs provided a brief history of vaccine approvals, how they impacted the distribution of *S. pneumoniae*, and why that has led to further development of new vaccines.

Prior to the 21st century, the only protection against pneumococcal disease was through the pneumococcal polysaccharide vaccine (PPSV), which originally was the 14-valent PPSV (PPSV14). That was later replaced by PPSV23 (Pneumovax 23) in 1983, according to the CDC.

However, protection against *S. pneumoniae* and pneumococcal disease wasn’t revolutionized until the year 2000, when the FDA approved the first PCV—Prevnar 7, or PCV7. This approval was crucial for populations most at risk of pneumococcal disease because of PCVs’ ability to outperform PPSVs.

“[Before PCVs], there was only a polysaccharide [vaccine], which was Pneumovax 23. We can't really get polysaccharide vaccines to a child, because it just doesn't stick; it doesn't stay,” continued Grubbs. “Their memory cells do not remember. We only could give those patients conjugate vaccines.”

Protecting against 7 of S. pneumoniae’s 100-plus serotypes, PCV7 was at first a saving grace for pediatric populations. However, protection began waning by 2005, opening the door for development of PCV13 (Prevnar 13), which protected against the same 7 serotypes as PCV7, plus an additional 6 serotypes (1, 3, 5, 6A, 7F, and 19A).

This trend in vaccine development and serotype shifts, as Grubbs hammered home throughout most of her presentation, has continued since. According to her, these trends are expected to continue throughout most working pharmacists’ careers.

Today, there are 3 different PCVs available for both the pediatric and older adult populations, including PCV15, PCV20, and PCV21. PPSV23 is also available for children 2 to 18 or for older adults that have already received PCV13 or PCV15. With 4 vaccines currently available for protection against pneumococcal disease, Grubbs helped NCPA attendees understand the proper approaches for PCV recommendations and how real-world data backs the use of specific vaccine regimens for certain populations.

“The question should be, ‘Are we covering the right serotypes that we're seeing currently?’ That's what, as clinicians, we need to think about and do the research, create the package inserts, [and] see if the right serotypes are being covered,” said Grubbs. “Because of this, we're seeing Prevnar 20 having about 52% coverage of the current cases we're seeing where Capvaxive is going to be covering 84% of the serotype coverage that we're seeing here in the US.”

Throughout her presentation, Grubbs focused on the 2 most utilized pneumococcal vaccines for US adults: PCV21 (Capvaxive) and PCV20 (Prevnar 20). As serotype distribution among the population evolves over time, vaccine manufacturers have also shifted which serotypes their products protect against. According to the serotypes that are common among S. pneumoniae infections, PCV21 has been found to protect against 84% of all current serotypes, while PCV20 covers just 52%.

“We see 50 is that age where we see that high risk,” Grubbs continued. “[A] patient walks in your pharmacy,

they're healthy as a horse, they are 50 years of age, [and] we vaccinate with Capvaxive (PCV21)."

While all vaccine recommendations for PCVs are significantly reliant on age, vaccination history, health conditions, and more, personalized approaches for each patient-pharmacist relationship are crucial for the promotion of pneumococcal immunization. Despite PCV20 being the better option in some situations, and vice versa, PCV21's ability to protect against 32% more serotypes than PCV20 shows that the former is often the proper recommendation for the adult and at-risk populations.

"With every CDC recommendation, it is just a recommendation for the current. It's very interesting. [In] all 15 years of my career, I never understood the 5-year thing," concluded Grubbs. "It actually makes sense. Every 5 years, we see that [serotype] shift, and you have to reevaluate. Do we need a new vaccine?"

Fuente: DRUG TOPICS. Disponible en https://goo.su/5yeEw

The Pan American Health Organization and Resolve to Save Lives convene eight countries in Panama to strengthen infectious outbreak preparedness in the Americas

Oct 20. With the aim of strengthening notification and response capacities for outbreaks and health emergencies in South and Central America, the Pan American Health Organization (PAHO) and Resolve to Save Lives convened delegates from eight countries for a three-day technical workshop held from 14 to 16 October in Panama City. The meeting focused on deepening the use of Early Action Review (EAR) data, applying the 7-1-7 Alliance methodology. Representatives from Brazil, Colombia, Costa Rica, El Salvador, Panama, Paraguay, Nicaragua, and Uruguay participated in the workshop.

This workshop is part of the framework cooperation agreement signed in May 2025 between PAHO and Resolve to Save Lives to implement and institutionalize EARs in support of the 7-1-7 objective. These precision measures are critical for enabling countries to work quickly, decisively, and collaboratively to prevent epidemics and save lives.

The 7-1-7 Alliance is a global initiative designed to improve early detection and rapid response to infectious disease outbreaks and other public-health threats. Its name reflects three concrete time-bound targets:

- 7 days to detect an unusual public-health event or outbreak
- 1 day to notify the appropriate authorities
- 7 days to initiate and complete early response actions

PAHO is a member of the Alliance, which is led by countries and supported by a broad network of partners, including governments, national public-health institutes, emergency operations centers, and global health organizations such as Resolve to Save Lives.

The Early Action Reviews (EARs) evaluate the speed with which a country detects and contains multi-hazard events and infectious diseases. EARs set clear benchmarks for early detection, notification, and response. Their simplicity, focus, and clarity have led to their inclusion in the PAHO Strategic Plan 2026–2031 and in the Pandemic Fund results framework.

During the workshop in Panama, countries discussed data-use tools and analytical approaches, shared lessons learned from EAR implementation, and developed country-specific roadmaps for next steps.

"A key outcome of this workshop was the validation of a generic protocol to institutionalize EARs in our region. The eight participating countries now have the experience needed to support sustainable implementation," said Andrea Villalobos, Acting PAHO Representative in Panama.

The workshop also included the participation of Andrew Gall, Senior Technical Advisor at Resolve to Save Lives, and his team, as well as José Renán De León Cáceres, Executive Secretary of COMISCA, and members of his technical team.

Fuente: PAHO. Disponible en https://goo.su/UQNtUof

Descubren que una vacuna de ARNm contra la COVID-19 genera una respuesta inmune para combatir el cáncer

21 oct. Una vacuna de ARN mensajero contra la COVID-19 mostró una respuesta inmune para combatir el cáncer, según un estudio de la Universidad de Florida y el Centro Oncológico MD Anderson de la Universidad de Texas, en Estados Unidos.

Los médicos observaron que, pacientes con cáncer avanzado de pulmón o de piel que recibieron la vacuna dentro de los 100 días de haber comenzado a tomar medicamentos de inmunoterapia, vivieron "significativamente más" que los que no recibieron la vacuna.

De acuerdo con un comunicado de la Universidad de Florida, este hallazgo "marca un hito en más de una década de investigación que prueba terapias basadas en ARNm diseñadas para 'despertar' el sistema inmunitario contra el cáncer".

Por ahora, los resultados son preliminares, pero de validarse en un ensayo clínico aleatorio, podría propiciar nuevos tratamientos contra el cáncer, señalan.

¿Qué descubrieron?

Los resultados del estudio fueron presentados el 19 de octubre en el Congreso de la Sociedad Europea de Oncología Médica 2025 en Berlín, Alemania. Por el momento, no se ha publicado.

Se trató de un estudio observacional que analizó datos ya existentes de pacientes con cáncer de pulmón y melanoma metastásico.

El quipo de investigadores notó que quienes recibieron una vacuna de ARNm contra la COVID-19, dentro de los 100 días de haber comenzado un tratamiento con medicamentos de inmunoterapia, tenían una vida significativamente más larga.

Además, esto también ocurrió en pacientes que no se esperaba que tuvieran una respuesta inmune fuerte al tratamiento, debido a la complejidad de sus tumores y otros factores.

En concreto, se analizaron registros de 180 pacientes con cáncer de pulmón avanzado que recibieron la vacuna en el periodo mencionado del tratamiento contra el cáncer y otros datos de 704 pacientes sin la vacuna.

Encontraron que recibir la vacuna se asoció con una supervivencia media de casi el doble, de 20,6 meses a 37,3 meses. En el caso de los pacientes con melanoma metastásico, con la vacuna, la supervivencia aumentó de 26,7 meses a un rango de 30-40.

¿Cómo la vacuna ARNm de la COVID-19 combate el cáncer?

Cabe señalar que las vacunas de ARNm de la COVID-19 , dirigen a las células para producir copias de una proteína en el exterior del coronavirus conocida como “proteína spike”, creando así anticuerpos que luego eliminan el virus en caso de un contagio.

Los científicos probaron combinar los fármacos de inmunoterapia con la vacuna en modelos murinos y esto mostró que puede transformar cánceres insensibles en cánceres receptivos, impidiendo el crecimiento tumoral.

“Uno de los mecanismos de cómo funciona esto es cuando se administra una vacuna de ARNm, que actúa como un foco que empieza a mover todas estas células inmunes desde áreas malas como el tumor a áreas buenas como los ganglios linfáticos”, explica Elias Sayour, oncólogo pediátrico de UF Health e investigador principal del estudio.

Ahora, esperan llevar a cabo un ensayo clínico para confirmar estos hallazgos. “Las implicaciones son extraordinarias: esto podría revolucionar por completo el campo de la atención oncológica“, manifestó Sayour.

Si realmente funciona “podríamos diseñar una vacuna inespecífica aún mejor para movilizar y restablecer la respuesta inmunitaria, de manera que, en esencia, se convirtiera en una vacuna universal y lista para usar contra el cáncer, para todos los pacientes con cáncer”, planteó.

Fuente: BioBio Chile.cl. Disponible en https://goo.su/VswO3

Artículos científicos publicados en Medline

Estrategia de búsqueda: *(vaccine[Title/Abstract]) AND (("2025/10/13"[Date - Publication]: "2025/10/21"[Date - Publication])) 279 records*

Yellow Fever **Vaccine**-Associated Viscerotropic Disease: A Unique Case of Atraumatic Splenic Rupture.
Nortey E, Bediako EM, Mould GK, Mills-Annoh A, Ekremet K, Kyei-Baffour P, Ekem A, Clarke JCA, Apaloo EFEK, Quartey-Papafio S. Case Rep Infect Dis. 2025 Oct 13;2025:7286972. doi: 10.1155/crdi/7286972. eCollection 2025. PMID: 41122203 Free PMC article.

Addressing Unmet Needs in Clostridium difficile Infection: Advances in Diagnosis, Treatment, and Prevention.
Sahoo A, Singh J, Alam K, Alruwaili NK, Aodah A, Almalki WH, Almujri SS, Alrobaian M, Barkat MA, Singh T, Lal JA, Rahman M. Curr Med Chem. 2025 Oct 17. doi: 10.2174/0109298673381785251008222034. Online ahead of print. PMID: 41121479

Qualitative investigation of academic routines and mental health among medical students following coronavirus vaccination.
Felix SN, Costa APL, Andrade JM, Correia AT, Costa FMA, Kobayasi R, Garcia MLB, Ballester D, de Arruda Martins M, Tempski PZ, Tibério IFLC, Romanholo BMS. BMC Psychol. 2025 Oct 21;13(1):1162. doi: 10.1186/s40359-025-03499-x. PMID: 41121400

Endothelial leak and knowledge gaps: yellow fever virus non-structural protein 1 and the antibodies that bind it.
Osman SR, Messer WB. Virol J. 2025 Oct 21;22(1):338. doi: 10.1186/s12985-025-02955-9. PMID: 41121181

Capturing the spatiotemporal spread of COVID-19 in 30 European countries during 2020 - 2022.
Nguyen THT, Hens N, Faes C. BMC Public Health. 2025 Oct 21;25(1):3547. doi: 10.1186/s12889-025-24795-6. PMID: 41121036

Strategies and challenges for immunisation of children under 5 years in primary health care in different countries: a scoping review.
Freitas CAM, Vilasbôas ALQ, de Brito Lima Prado NM. BMC Public Health. 2025 Oct 21;25(1):3558. doi: 10.1186/s12889-025-24846-y. PMID: 41121034

Predictors of **vaccine** hesitancy among medical students at the University of Belgrade.
Nikolić A, Šipetić Grujičić S, Tanula AM, Vujčić I, Marušić V, Majcan M. BMC Med Educ. 2025 Oct 21;25(1):1471. doi: 10.1186/s12909-025-08028-3. PMID: 41121012

Cost effectiveness of female HPV vaccines for routine childhood immunisation schedule in Türkiye.
Şahin ÇE, Karabey S. BMC Public Health. 2025 Oct 21;25(1):3561. doi: 10.1186/s12889-025-24878-4. PMID: 41120978

Real world effectiveness of antipneumococcal vaccination against pneumonia in adults: a population-based cohort study, Catalonia, 2019.
de Diego-Cabanes C, Torras-Vives V, Vila-Córcoles A, Satué-Gracia EM, Forcadell-Peris MJ, Gómez-Bertomeu F, de Esteban-Júlvez L, Hospital-Guardiola I, Fuentes-Bellido CM, Ribes-Alcover A, Rodriguez-

Casado C, Ochoa-Gondar O. BMC Infect Dis. 2025 Oct 21;25(1):1369. doi: 10.1186/s12879-025-11596-w. PMID: 41120971

Barriers and facilitating factors for COVID-19 vaccination in rural appalachia.
Cardarelli KM, Gillespie R, Hoover AG, Francis DB, Kiviniemi MT. BMC Public Health. 2025 Oct 21;25(1):3545. doi: 10.1186/s12889-025-24484-4. PMID: 41120921

MicroRNA expression dynamics in mouse liver at different stages of Echinococcus multilocularis infection.
Chen Y, Gao HJ, Li C, Mo XJ, Zheng GR, Xie J, Gao J, Bold B, Feng Z, Zhang T, Hu W. BMC Genomics. 2025 Oct 21;26(1):941. doi: 10.1186/s12864-025-12049-z. PMID: 41120833 Free article.

Impact of health education on knowledge and perception of cervical cancer and screening among rural women in Bangladesh.
Mili MA, Hossain MJ, Poli MA, Kumar SB, Bhowmick B, Kundu LR. Sci Rep. 2025 Oct 21;15(1):36812. doi: 10.1038/s41598-025-20676-5. PMID: 41120629 Free article.

Reverse vaccinology-driven construction and bioinformatics validation of a multi-epitope **vaccine** against Brucella spp.
Chai ZL, Qi XX, Li R, Luo JR, Li C, Shi HD, Tian TT, Shang KY, Zhu YJ, Zhang FB. Sci Rep. 2025 Oct 21;15(1):36663. doi: 10.1038/s41598-025-20507-7. PMID: 41120486 Free article.

Optimal strategies for managing Hepatitis B Virus (HBV) infection: a comprehensive approach through education, vaccination, and therapy.
Alsinai A, Niazi AUK, Uroej S, Ahmed B. Sci Rep. 2025 Oct 21;15(1):36683. doi: 10.1038/s41598-025-20298-x. PMID: 41120448 Free article.

B-cell epitope mapping of Orthoflavivirus zikaense in mother-newborn immune interaction reveals postnatal immune signatures.
Soares AP, Chávez-Olórtegui C, de Lima Neto DF, Dos Passos Cunha M, Grillo TC, da Silva MF, Silva ACB, Bertozzi APAP, Bonafé CFS, Passos SD, de Andrade Zanotto PM. Sci Rep. 2025 Oct 21;15(1):36530. doi: 10.1038/s41598-025-16702-1. PMID: 41120442 Free article.

Association between COVID-19 vaccination status and mortality in hospitalised COVID-19 patients during the Omicron period: a retrospective cohort study in Taiwan.
Chang MH, Ko SC, Liao KM, Ho CH. BMJ Open. 2025 Oct 20;15(10):e094412. doi: 10.1136/bmjopen-2024-094412. PMID: 41120151 Free article.

How community engaged practices are applied in interventions promoting human papillomavirus (HPV) vaccination for culturally and linguistically diverse (CALD) children and adolescents: a systematic review.
Prokopovich K, Braunack-Mayer A, Phillipson L. Ethn Health. 2025 Oct 21:1-29. doi: 10.1080/13557858.2025.2573914. Online ahead of print. PMID: 41120133

Hospital-Based Surveillance of Pediatric Invasive Pneumococcal Diseases, 2016-2023 in Korea: Serotype Trends and Vaccination Policy.
Kang D, Yun KW, Lee H, Song ES, Ahn JG, Park SE, Lee T, Cho HK, Lee J, Kim YJ, Jo DS, Kang HM, Lee JK, Kim CS, Kim DH, Choi JH, Eun BW, Kim NH, Cho EY, Kim YK, Kim HW, Choi EH. J Korean Med Sci. 2025 Oct 20;40(40):e250. doi: 10.3346/jkms.2025.40.e250. PMID: 41120105

Giving the respiratory syncytial virus F protein a precision cut: A step toward a rational **vaccine** design for focused immune responses.
Ahmed AU. Mol Ther. 2025 Oct 20:S1525-0016(25)00839-1. doi: 10.1016/j.ymthe.2025.10.018. Online ahead of print. PMID: 41118762

Knowledge and Perception of Human Papillomavirus in Quilombola Communities in Northeast Brazil.
de Campos MR, Carvalho LHSB, Campos AJR, Côra GR, Machado RA, Elehamer NMK, Villa LL, Ross JR, Vidal FCB. Hisp Health Care Int. 2025 Oct 21:15404153251383132. doi: 10.1177/15404153251383132. Online ahead of print. PMID: 41118537

Caregivers' practices and factors associated with malaria **vaccine** uptake among under-five children in the Tiko Health District, Cameroon: A community based cross-sectional study.
Abiache IM, Nsobinenyui D, Ukah CE, Kumenyuy YL, Ngeha NC, Wefuan R, Dang SZ, Ndip NE, Feguem MP, Nsagha DS. PLOS Glob Public Health. 2025 Oct 21;5(10):e0004695. doi: 10.1371/journal.pgph.0004695. eCollection 2025. PMID: 41118415

Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humans.
Grobben M, Reiss EIMM, Schriek AI, van der Straten K, Dereuddre-Bosquet N, Maisonnasse P, Rooker A, Yu C, Tejjani K, Tolazzi M, Sliepen K, Felfödiné Lévai R, Farsang A, Le Grand R, Scarlatti G, Shattock RJ, de Taeye SW, de Bree GJ, Sanders RW, van Gils MJ. PLoS Pathog. 2025 Oct 21;21(10):e1013614. doi: 10.1371/journal.ppat.1013614. Online ahead of print. PMID: 41118401

Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes.
Carter JJ, Hurlburt NK, Scherer EM, Singh S, Rodarte JV, Smith RA, Lewis P, Kinzelman R, Kieltyka J, Cabã ME, Wipf GC, Pancera M, Galloway DA. PLoS Pathog. 2025 Oct 21;21(10):e1013086. doi: 10.1371/journal.ppat.1013086. Online ahead of print. PMID: 41118367

Differential Odds of COVID-19 Infection Associated with Household and Workplace Exposures in U.S. Health Care Personnel.
Kontowicz E, Irish AK, Plumb ID, Briggs-Hagen M, Harland KK, Krishnadasan A, Talan DA, Ten Eyck P, Steele MT, Kean ER, Mohr NM; and Project PREVENT Network. J Occup Environ Med. 2025 Oct 21. doi: 10.1097/JOM.0000000000003586. Online ahead of print. PMID: 41118238

Correction: Associations Between General **Vaccine** Hesitancy and Healthcare Access Among Arkansans.
McElfish PA, Selig JP, Scott AJ, Rowland B, Willis DE, Reece S, CarlLee S, Macechko MD, Shah SK. J Gen Intern Med. 2025 Oct 21. doi: 10.1007/s11606-025-09948-y. Online ahead of print. PMID: 41118121

High Specific Real-Time Tracking of Single Virus Particles.
Hong E, Jang G, Lin C, Rao S, Wang Q. ACS Nano. 2025 Oct 21. doi: 10.1021/acsnano.5c11017. Online ahead of print. PMID: 41117904

Expanding modeling boundaries to design more resilient **vaccine** supply networks.
Guttieres D, Van Riet C, Vandaele N, Decouttere C. Health Care Manag Sci. 2025 Oct 21. doi: 10.1007/s10729-025-09726-6. Online ahead of print. PMID: 41117859

Investigational treatments for cytomegalovirus infection in phase I and II study.
Hakki M, Stern A, Papanicolaou GA. Expert Opin Investig Drugs. 2025 Oct 21. doi: 10.1080/13543784.2025.2579018. Online ahead of print. PMID: 41117825

Immunoregulation mediated by the enzyme inhibitory activity of helminth-derived serine protease inhibitor affects the protective efficiency of vaccines.
Shi W, Liu Y, Bai X, Liang Y, Zhang S, Sun L, Lin W, Liu X, Xu N. Virulence. 2025 Dec;16(1):2569621. doi: 10.1080/21505594.2025.2569621. Epub 2025 Oct 21. PMID: 41117767

Estimated **Vaccine** Effectiveness for Respiratory Syncytial Virus-Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season.
Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B, Liu Q, Shaw S, Welsh S, Kapadia B, Spence BC, Lewnard JA, Davis GS, Aragones M, Dutro M, Chilson E, Gonzalez E, Hubler R, Jodar L, Gessner BD, Begier E. Clin Infect Dis. 2025 Oct 21:ciaf496. doi: 10.1093/cid/ciaf496. Online ahead of print. PMID: 41117531

A unified topology-based classification of SARS-CoV-2 RBD neutralizing antibodies systematizes affinity trends across variants.
Cofas-Vargas LF, Mendoza-Espinosa P, Montalvo-Sandoval FD, Pérez-Rodríguez S, Rauda-Ceja JA, Hernández-Peralta P, Durán-Vargas A, Trujillo-Roldán MA, Valdez-Cruz NA, García-Hernández E. MAbs. 2025 Dec;17(1):2575083. doi: 10.1080/19420862.2025.2575083. Epub 2025 Oct 21. PMID: 41117360

An Anti-IL-13 **Vaccine** Reduces Atopic Dermatitis in Humanized Mice and Induces Neutralizing Antibodies in Nonhuman Primates.
Mougel A, Lemdani K, Serhan N, Hateb C, Bonnefoy J, Hamdi S, Worrall WPM, Kamphuis JBJ, Andrieux L, Colaone F, Vieira R, Zahm M, Chaubet A, Lachambre S, Ekren R, Leveque E, Guilleminault L, Gaudenzio N, Drouet B, Serra V, Reber LL. Allergy. 2025 Oct 21. doi: 10.1111/all.70110. Online ahead of print. PMID: 41117068

Disseminated Varicella-Zoster Virus Infection in Organ Transplant Recipients: A 10-year Retrospective Study.
Yamamuro R, Romero A, Khandelwal-Young A, Humar A, Kumar D. Transpl Infect Dis. 2025 Oct 21:e70117. doi: 10.1111/tid.70117. Online ahead of print. PMID: 41117030

Leveraging immunoinformatic for the rational design of highly immunogenic multi-epitope subunit vaccines against Dugbe virus: a molecular docking and simulation approach.
Khan A, Khan SU, Akbar F, Hassan F, Ali Z, Khan H, Ali S, Yousaf M, Yassine HM, Crovella S, Suleman M. In Silico Pharmacol. 2025 Oct 18;13(3):158. doi: 10.1007/s40203-025-00439-w. eCollection 2025. PMID: 41116866

Formulation and Immunological Assessment of DNA Vaccines Utilising In Vivo-Induced Antigens Against Nocardia seriolae in Hybrid Snakehead (Channa maculata ♀ × Channa argus ♂).
Kang X, Chen G, Li N, Li Y, Xia L, Lu Y, Huang T, Chen J. J Fish Dis. 2025 Oct 20:e70074. doi: 10.1111/jfd.70074. Online ahead of print. PMID: 41116686

Which Care-Seekers are Prioritized for Preventive Maternal and Child Health Services in a Low-Resource Setting? A Vignette Experiment in Rural Guinea-Bissau.
Bærentzen AS, Nehal KR, Gomes DP, Helleringer S, Fisker AB, Damerow SM. Trop Med Int Health. 2025 Oct 20. doi: 10.1111/tmi.70054. Online ahead of print. PMID: 41116649

Solid-Phase Synthesized Imunofan Confers Clinically Relevant Protection using a Chimeric Protein **Vaccine** Candidate Against E. coli O157:H7 in BALB/c Mice.
Mansourabad AM, Samiei-Abianeh H, Tarverdizadeh Y, Aghaie SM, Hajizade A. Curr Protein Pept Sci. 2025 Oct 15. doi: 10.2174/0113892037405052250926104854. Online ahead of print. PMID: 41116267

RNA replicon vaccination confers long-lasting protection against H5N1 avian influenza in 23 zoo bird species.
Stettler M, Hoby S, Wenker C, Wyss F, Heiderich E, Butticaz L, Ruggli N, Darpel K, Zimmer G. Nat Commun. 2025 Oct 20;16(1):9245. doi: 10.1038/s41467-025-64301-5. PMID: 41115934 Free PMC article.

Condensate nanovaccine adjuvants augment CD8⁺ T-Cell-dependent antitumor immunity through mtDNA leakage-triggered cGAS-STING axis activation.
Tang Y, Luo Z, Ma Z, Han L, Zhou Y, Liang T, Yang K, Zhao L, Chen X, Zhang P. Signal Transduct Target Ther. 2025 Oct 21;10(1):349. doi: 10.1038/s41392-025-02447-w. PMID: 41115902 Free PMC article.

Addressing Faith-Based Concerns about Vaccination.
Cayley WE Jr. J Am Board Fam Med. 2025 Oct 20. doi: 10.3122/jabfm.2025.250038R1. Online ahead of print. PMID: 41115758

Comprehensive Review on How Repurposed Drugs Modulate Antitumor Immunity: Harnessing Damage-Associated Molecular Patterns.
Shaik R, Sappidi M, Vemula D, Munjala A, Syeda FS, Begum S, Khan H, Mandava K. Cancer Biother Radiopharm. 2025 Oct 20. doi: 10.1177/10849785251389355. Online ahead of print. PMID: 41115696

Defunding mRNA **vaccine** research leaves us all more vulnerable to future health emergencies.
Nuzzo JB. BMJ. 2025 Oct 20;391:r2183. doi: 10.1136/bmj.r2183. PMID: 41115694

Development and characterization of monoclonal antibodies against ASFV-encoded early protein pI73R.
Miao Y, Zhao P, Wang Z, Gao X, Chu J, He J, Dong Y, Qi C, Zhang Y, Hu Y, Qian Y, Wu X, Jung YS. Int J Biol Macromol. 2025 Oct 18:148373. doi: 10.1016/j.ijbiomac.2025.148373. Online ahead of print. PMID: 41115555

Berberine Inhibits Mycoplasma synoviae Infection by Suppressing PIK3CA-Dependent Inflammatory and Apoptotic Responses in Avian Macrophages.
Sun Y, Hu W, Li S, Kabir MA, Amevor FK, Wang Y, Jin W. Microb Pathog. 2025 Oct 18:108114. doi: 10.1016/j.micpath.2025.108114. Online ahead of print. PMID: 41115537

From HSV-2 to HSV1: a Change in the Epidemiology of Genital Herpes.
Andreu S, Galdo-Torres D, Ripa I, Caballero O, Bello-Morales R, López-Guerrero JA. J Infect. 2025 Oct 18:106636. doi: 10.1016/j.jinf.2025.106636. Online ahead of print. PMID: 41115532

COVID-19 in Retrospect: Public Health Lessons from a Global Crisis.
Bratzler DW. Am J Med Sci. 2025 Oct 18:S0002-9629(25)01248-0. doi: 10.1016/j.amjms.2025.10.008. Online ahead of print. PMID: 41115503

Effectiveness of high-dose influenza **vaccine** against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.
Johansen ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, Loiacono MM, Harris RC, Dufournet M, van Aalst R, Chit A, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Duran-Parrondo C, Piñeiro-Sotelo M, Cribeiro-González M, Conde-Pájaro M, Mirás-Carballal S, González-Pérez JM, Solomon SD, Sivapalan P, Martel CJ, Jensen JUS, Martinón-Torres F, Biering-Sørensen T; DANFLU-2 Study Group; GALFLU Trial Team. Lancet. 2025 Oct 17:S0140-6736(25)01742-8. doi: 10.1016/S0140-6736(25)01742-8. Online ahead of print. PMID: 41115437

A global landscape of patenting activity in COVID-19 vaccines.
Mercadante E, Minssen T, Shadlen KC, van Zimmeren E, Zemła-Pacud Ż, Matthews D. Vaccine. 2025 Oct 18;67:127866. doi: 10.1016/j.vaccine.2025.127866. Online ahead of print. PMID: 41115388

What Do I Need to Know About the Pneumococcal Pneumonia **Vaccine**?
Kneifati-Hayek JZ, Incze MA. JAMA Intern Med. 2025 Oct 20. doi: 10.1001/jamainternmed.2025.5277. Online ahead of print. PMID: 41114997

Resident memory macrophages and trained innate immunity at barrier tissues.
Kang A, D'Agostino M, Afkhami S, Jeyanathan M, Xing Z. Elife. 2025 Oct 20;14:e106549. doi: 10.7554/eLife.106549. PMID: 41114718 Free PMC article.

"It was tidak cocok (incompatible)": Incompatibility, Decoloniality, and **Vaccine** Hesitancy in Banda Aceh, Indonesia.
Romadhon DI. Med Anthropol Q. 2025 Oct 20:e70024. doi: 10.1111/maq.70024. Online ahead of print. PMID: 41114699

Safety monitoring of GSK's quadrivalent seasonal influenza **vaccine** in European countries during the 2023/24 flu season: A multicenter, non-interventional study.
Salamanca de la Cueva I, Brotons C, Maier P, Pirçon JY, Gupta V, Eckermann T, Nikic V, Martinez Gomez X, Alsdurf H. Hum Vaccin Immunother. 2025 Dec;21(1):2569735. doi: 10.1080/21645515.2025.2569735. Epub 2025 Oct 20. PMID: 41114673 Free article.

Cure of experimental *Trypanosoma vivax* infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX.
Autheman D, Viola C, Rhodes G, Clare S, Brandt C, Harcourt K, Wright GJ. mBio. 2025 Oct 20:e0206425. doi: 10.1128/mbio.02064-25. Online ahead of print. PMID: 41114596 Free article.

Pangenome analysis of Tanzanian clinical *Klebsiella pneumoniae* reveals pandemic clones with high genome plasticity and versatile mobilome, virulome, and resistome profiles.
Bahati SY, Maghembe RS. Microbiol Spectr. 2025 Oct 20:e0194725. doi: 10.1128/spectrum.01947-25. Online ahead of print. PMID: 41114504 Free article.

Designing a novel mRNA **vaccine** against foot-and-mouth disease using immunoinformatics approach.
Das S, Jagadeb M, Biswal JK. In Silico Pharmacol. 2025 Oct 17;13(3):151. doi: 10.1007/s40203-025-00444-z. eCollection 2025. PMID: 41113170

Rational Design and In Silico Evaluation of a Multiepitope **Vaccine** Targeting the uPAR for Cancer Immunotherapy.
Baghaei F, Hemmat Z, Taherkhani A, Shojaei S, Teimoori A. J Immunol Res. 2025 Oct 16;2025:9126083. doi: 10.1155/jimr/9126083. eCollection 2025. PMID: 41112949 Free PMC article.

Evasin and TSLPI Tick Salivary Antigen Subunit **Vaccine** Nanoparticles Induce Humoral and Cellular Immunity.
Park J, Pho T, Denisov SS, Dijkgraaf I, Champion JA. ACS Nanosci Au. 2025 Aug 12;5(5):337-343. doi: 10.1021/acsnanoscienceau.5c00034. eCollection 2025 Oct 15. PMID: 41112869 Free PMC article.

Recent Advances in Humoral Immunity Dysregulation in Severe Fever With Thrombocytopenia Syndrome Virus (SFTSV) Infection: A Systematic Review.
Hou H, Yuan X, Chen R, Xiong Z, Wu S, Wang F. Health Sci Rep. 2025 Oct 15;8(10):e71328. doi: 10.1002/hsr2.71328. eCollection 2025 Oct. PMID: 41112594 Free PMC article.

Describing diagnosis (MAT + PCR) and control (**vaccine** + streptomycin sulfate) of a leptospirosis outbreak in dairy cows with reproductive disorders.
Stein MA, Costa NB, da Silva GCP. Anim Reprod. 2025 Oct 17;22(4):e20250011. doi: 10.1590/1984-3143-AR2025-0011. eCollection 2025. PMID: 41112080 Free PMC article.

Evaluating the Immunological Properties of Recombinant Hepatitis B Surface Antigen Using a Multitiered *In Vivo* and *In Vitro* Approach.
Zhao X, Shao T, Li W, Ji H, Zeng Y, Cao C. Viral Immunol. 2025 Oct 17. doi: 10.1177/08828245251389235. Online ahead of print. PMID: 41111391

Development and validation of an agent-based cost-effectiveness model of varicella vaccination strategies in Australia.
Hodgkinson B, Scuffham P. J Med Econ. 2025 Oct 20:1-22. doi: 10.1080/13696998.2025.2577513. Online ahead of print. PMID: 41111311 Free article.

Knowledge, Attitudes, Practices and Perceptions of the Eco-Bio-Social Determinants of Dengue Transmission in São Paulo, Brazil: A Mixed-Methods Study.
Barkhad A, de Almeida Santos G, Roberto Costa Campos S, Maria Almeida Braz L, Picinini Freitas L, Zinszer K, de Souza R, Waldron I, Loeb M, Luna E, Mbuagbaw L. Trop Med Int Health. 2025 Oct 19. doi: 10.1111/tmi.70050. Online ahead of print. PMID: 41111250

CME: Hepatitis C.
Farooq HZ, Foster GR. Clin Med (Lond). 2025 Oct 17:100522. doi: 10.1016/j.clinme.2025.100522. Online ahead of print. PMID: 41110774 Free article.

Applying Spectral Analysis to the Arterial Pulse to Discriminate Cardiovascular Side Effects Following Administration of Moderna's mRNA-1273 **Vaccine**.
Chen CC, Chang WT, Chiu CC, Yang TY, Hao WR, Huang TW, Lin KJ, Fang YA, Hsu MH, Yang TL, Lai YH, Jong HC, Liu JC, Hsiu H. Eur J Pharmacol. 2025 Oct 17:178269. doi: 10.1016/j.ejphar.2025.178269. Online ahead of print. PMID: 41110748

Association of Influenza Vaccination With Acute Kidney Injury: A Prospective Target Trial Emulation Study.
Zhuo L, Zhang B, Huang Y, Wen Q, Wang S, Zhan S, Zhao H. Am J Kidney Dis. 2025 Oct 17:S0272-6386(25)01078-9. doi: 10.1053/j.ajkd.2025.09.005. Online ahead of print. PMID: 41110628 Free article.

HIV status is not associated with SARS-CoV-2 viral load and longer duration of infection among people with well-controlled HIV and high COVID-19 **vaccine** coverage.
Deb D, Heidari ME, Kizito B, Kesamang M, Matila T, Matsheka M, Niemann S, Shin SS, Modongo C. Int J Infect Dis. 2025 Oct 17:108142. doi: 10.1016/j.ijid.2025.108142. Online ahead of print. PMID: 41110590 Free article.

What About **Vaccine**-Experienced Younger Adults? Cost-Effectiveness of PCV21 Use in **Vaccine**-Experienced US Adults Aged 19-64 Years with Underlying Medical Conditions.
Yi Z, Elbasha EH, Owusu-Edusei K. Am J Prev Med. 2025 Oct 17:108159. doi: 10.1016/j.amepre.2025.108159. Online ahead of print. PMID: 41110559 Free article.

A multivalent nanoparticle **vaccine** elicits potent neutralizing antibody response against monkeypox virus.
Yuan RY, Li MJ, Lin XB, Yu F, Ding Y, Yang Y, Shen CG, Zhang H, Kang YF. J Control Release. 2025 Oct 17:114339. doi: 10.1016/j.jconrel.2025.114339. Online ahead of print. PMID: 41110472

Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.
Anosike C, Ojiakor IM, Etiaba EI, Uguru NP, Ezenduka CC, Onwujekwe O. Vaccine. 2025 Oct 18;67:127853. doi: 10.1016/j.vaccine.2025.127853. Online ahead of print. PMID: 41110197

Corrigendum to "Changes in pneumococcal vaccination disparities by area-level social vulnerability during the COVID-19 pandemic among Medicare and Medicaid enrollees" [**Vaccine** 62 (2025) 127452].
Mohanty S, Zurovac J, Barna M, Cossrow N, Fiduccia PC, Cassell K, Smith-Howell E, McGuinn VC, Chatrath S, Shanmugam P, Keshaviah A, Poznyak D, Evans A, Feemster KA. Vaccine. 2025 Oct 18;67:127875. doi: 10.1016/j.vaccine.2025.127875. Online ahead of print. PMID: 41110196

Contributing factors to reversed willingness to vaccinate after the COVID-19 pandemic: Insights from a national panel survey.
Oikawa K, Murakami M, Ochi S, Yamagata M, Miura A. Vaccine. 2025 Oct 18;67:127869. doi: 10.1016/j.vaccine.2025.127869. Online ahead of print. PMID: 41110195 Free article.

The Impact of COVID-19 **Vaccine** Myths and Conspiracy Theories on **Vaccine** Hesitancy and **Vaccine** Refusal in Turkey: Future Implications.
Parlak AG, Gökçay G, Karacan Y. Public Health Nurs. 2025 Oct 19. doi: 10.1111/phn.70030. Online ahead of print. PMID: 41109980

CircRNA: Unlocking New Frontiers in Therapeutic and **Vaccine** Development.
Bahrulolum H, Rouzbahani FN, Hoseini ZS, Chaharmahali M, Hosseini SM. Mol Ther. 2025 Oct 17:S1525-0016(25)00859-7. doi: 10.1016/j.ymthe.2025.10.038. Online ahead of print. PMID: 41109952

Vaccine immunotherapy for glioblastoma: How can previous attempts guide us?
Leite E Silva MH, Siqueira IA, Kucaniz RR, Dos Santos DSR, da Silva MAB, Menezes V, Mamede M. Exp Neurol. 2025 Oct 16:115509. doi: 10.1016/j.expneurol.2025.115509. Online ahead of print. PMID: 41109657

The quadruple gene mutant (aerA-ahh1-rtxA-th) of Aeromonas dhakensis shows reduced virulence and promising **vaccine** development potential.
Feng W, Huang S, Yi A, Wang X, Wu Y, Li X, Yang N, Fan L, Guo G, Zheng J. Fish Shellfish Immunol. 2025 Oct 16:110952. doi: 10.1016/j.fsi.2025.110952. Online ahead of print. PMID: 41109542

Host-pathogen interplay in African swine fever virus: Immune evasion and genetic resistance driving prevention and control strategies.
Arutkumaran S, Deb R, Shanmathi S, Sengar GS, Chakravarti S, Das PJ, Pegu SR, Reis AL, Gupta VK. Microb Pathog. 2025 Oct 16;209:108119. doi: 10.1016/j.micpath.2025.108119. Online ahead of print. PMID: 41109467

Optimization of Rabies Virus Production in Neuroblastoma Cells using Quality by Design Principles for **Vaccine** and Diagnostic Applications.
Ugeda N, Ribeiro OG, Fernandes ER, Guedes F, Dos Ramos Silva S, Katz ISS. J Virol Methods. 2025 Oct 16:115289. doi: 10.1016/j.jviromet.2025.115289. Online ahead of print. PMID: 41109453

Hepatitis A breakthrough infections despite vaccination - a systematic review and meta-analysis.
Schnyder JL, Hutten D, Bache BE, Spijker R, Welkers MRA, de Jong HK, Grobusch MP, Goorhuis A. Int J Infect Dis. 2025 Oct 16:108113. doi: 10.1016/j.ijid.2025.108113. Online ahead of print. PMID: 41109412 Free article.

Validation of High-throughput Oxford Nanopore Technology for HIV-1 Transmitted/Founder Virus Identification.
Byamukama D, Ndekezi C, Omara D, Nakyanzi A, Natwijuka F, Kato F, Mugaba S, Kimuda MP, Kapaata A, Nduati E, Kaleebu P, Balinda SN. Int J Infect Dis. 2025 Oct 16:108138. doi: 10.1016/j.ijid.2025.108138. Online ahead of print. PMID: 41109409 Free article.

SEROLOGIC SCREENING FOR ANTI-RUBELLA IgG ANTIBODIES IN ROMANIAN PREGNANT WOMEN: AN UNEXPECTED RATE OF SERONEGATIVITY.
Morariu LM, Lupu MA, Craciun AC, Oprea MO, Chiriac DV, Olariu TR. Int J Infect Dis. 2025 Oct 16:108137. doi: 10.1016/j.ijid.2025.108137. Online ahead of print. PMID: 41109406 Free article.

EtMIC2 overexpression attenuates pathogenicity while enhancing oocyst production and immunogenicity in Eimeria tenella.
Qiao Y, Wang J, Zhao Q, Zhu S, Yu Y, Wu S, Zhao F, Han W, Bai J, Han H, Dong H. Int J Biol Macromol. 2025 Oct 16:148361. doi: 10.1016/j.ijbiomac.2025.148361. Online ahead of print. PMID: 41109389

Corrigendum to "Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort" [**Vaccine** 62 (2025) 127580].
Killander Möller I, Hedberg P, Wagner P, Sparén P, Gisslén M, Nauclér P, Aleman S, Bergman P, Carlander C; CLHIP study group. Vaccine. 2025 Oct 17;67:127855. doi: 10.1016/j.vaccine.2025.127855. Online ahead of print. PMID: 41109152 Free article.

Parental perceptions and willingness to pay for childhood vaccination experiences in China: a multi-city comprehensive evaluation study.
Liu B, Huang N, Liu Y, Zhang X, Wu B, Cao B, Sun T, Miao Y, Cui F. Vaccine. 2025 Oct 17;67:127826. doi: 10.1016/j.vaccine.2025.127826. Online ahead of print. PMID: 41109151

Diagnostic value of five Mycobacterium tuberculosis dormant highly expressed antigens in latent infections and immunogenicity assessment of a novel subunit **vaccine** PB2-DIMQ.
Zhong Q, Wang X, Xu Y, Wang R, Zhou M, Liu X. Tuberculosis (Edinb). 2025 Oct 14;155:102698. doi: 10.1016/j.tube.2025.102698. Online ahead of print. PMID: 41108940

A chemiluminescence immunoassay for detecting neutralizing antibodies of foot-and-mouth disease virus serotype A.
Sun M, Bao Y, Li K, Zuo Y, Zhang H, Fu Y, Li P, Sun P, Zhao Z, Jiang T, Bai X, Lin M, Lu Z, Cao Y. Appl Microbiol Biotechnol. 2025 Oct 18;109(1):232. doi: 10.1007/s00253-025-13616-w. PMID: 41108374 Free PMC article.

Prevalence characteristics of human papillomavirus among women in Henan Province of China.
Zhu X, Li S, Zhuang C. Virol J. 2025 Oct 17;22(1):332. doi: 10.1186/s12985-025-02953-x. PMID: 41107974 Free PMC article.

Associations of socioeconomic factors with parents' awareness and acceptability of HPV vaccination in sub-Saharan Africa - a systematic review and meta-analysis.
John A, Abbah AP, Sandøy IF. BMC Public Health. 2025 Oct 17;25(1):3525. doi: 10.1186/s12889-025-24550-x. PMID: 41107838 Free PMC article.

Factors influencing pediatric COVID-19 vaccination uptake: a quantitative investigation in the Philippines.
Lota MM, Acacio-Claro PJ, Vogt F, Roxas E, Abeleda A, Dalisay SN, Landicho M, Fujimori Y, Rosuello JZ, Kaufman J, Danchin M, Belizario V Jr. BMC Public Health. 2025 Oct 17;25(1):3529. doi: 10.1186/s12889-025-24654-4. PMID: 41107807 Free PMC article.

Physicians' knowledge of, and willingness to encourage caregivers to partake in the RTS S/AS01 and R21 matrix M malaria vaccines roll out - a national survey in Nigeria.
Oboh MA, Adeleke OT, Adeleke OV, Awotunde TA. BMC Infect Dis. 2025 Oct 17;25(1):1345. doi: 10.1186/s12879-025-11760-2. PMID: 41107776 Free PMC article.

Risk factors of COVID-19 breakthrough infection: a case-control test-negative design study.
Tejada-Panduro G, Pinós-Tella L, Otero-Romero S, Borras-Bermejo B, Carbones I, Antón A, Andrés C, Parés-Badell O. BMC Infect Dis. 2025 Oct 17;25(1):1346. doi: 10.1186/s12879-025-11773-x. PMID: 41107762 Free PMC article.

Artificial intelligence in biology and medicine.
Iskuzhina L, Turaev Z, Rozhin A, Romanov A, Skomorokhova E, Ishmukhametov I, Rozhina E. Naturwissenschaften. 2025 Oct 17;112(6):80. doi: 10.1007/s00114-025-02029-4. PMID: 41107683

Immunodeficiencies in Adults: Key Considerations for Diagnosis and Management.
Regina J, Doms J, Kampouri E, Gerber C, Manuel O, Bart PA, Candotti F, Comte D. Clin Rev Allergy Immunol. 2025 Oct 17;68(1):92. doi: 10.1007/s12016-025-09103-9. PMID: 41107625 Free PMC article.

Progress in cancer vaccines enabled by nanotechnology.
Kim BJ, Abdelfattah NS, Hostetler A, Irvine DJ. Nat Nanotechnol. 2025 Oct 17. doi: 10.1038/s41565-025-02021-z. Online ahead of print. PMID: 41107547

Impaired antibody responses to heterologous ChAdOx1 nCoV-19 and BNT162b2 vaccination in individuals with type 2 diabetes.
Saenwongsa W, Kingpha S, Saythanu P, Sopila S, Lertmemongkolchai G, Kewcharoenwong C. Sci Rep. 2025 Oct 17;15(1):36395. doi: 10.1038/s41598-025-20324-y. PMID: 41107384 Free PMC article.

Differences in local immune response of bait Mycobacterium bovis heat-inactivated vaccinated badgers showing exacerbated tuberculous lesions after challenge.
Barroso P, Juste R, Sañudo B, Bonnaire D, Herrero-García G, Blanco-Vázquez C, Barral M, Lesellier S, Davé D, Garrido J, Sevilla IA, Casais R, Balseiro A. Sci Rep. 2025 Oct 17;15(1):36329. doi: 10.1038/s41598-025-20278-1. PMID: 41107375 Free PMC article.

Hepatitis A in Central Argentina: Anti-HAV prevalence in adults living in a region of low endemicity 17 years after the official introduction of the **vaccine**.
Castro GM, Mamani V, Mariojouls Bringas J, Chumacero P, Díaz P, Scruzzi G, Martínez Wassaf M, Borda MA, López L, Gabriela Barbás M, Belén Pisano M, Ré VE. Rev Argent Microbiol. 2025 Oct 16:S0325-7541(25)00092-6. doi: 10.1016/j.ram.2025.08.002. Online ahead of print. PMID: 41107103 Free article.

Associations between serum metals and antibody levels against measles, rubella, and varicella vaccines in children with sex-specific nonlinear patterns.
Liu M, Zhu P, Deng F, Liang B, Xu Y, Qin P, Peng R, Tan L. Environ Pollut. 2025 Oct 15;386:127276. doi: 10.1016/j.envpol.2025.127276. Online ahead of print. PMID: 41106800

An overview of needle-free injection technology in human vaccines.
Ma W, Hu ZB, Zhu N, Yu Y, Shen W, Fang WJ. Int J Pharm. 2025 Oct 15:126287. doi: 10.1016/j.ijpharm.2025.126287. Online ahead of print. PMID: 41106514

Don't forget to floss! An innovative approach for **vaccine** delivery.
Hickman HD, Moutsopoulos NM. Cell. 2025 Oct 16;188(21):5787-5789. doi: 10.1016/j.cell.2025.09.008. PMID: 41106358

Synthetic peptide vaccines targeting SVA elicit robust protective immune responses in swine.
Li Y, Cao N, Yin B, Ji M, Liu X, Liu S, Jiao M, Li X, Qian P. Vet Microbiol. 2025 Oct 13;311:110763. doi: 10.1016/j.vetmic.2025.110763. Online ahead of print. PMID: 41106188

Hesitancy towards routine childhood vaccinations before and after the COVID-19 pandemic in Arkansas.
Cima MJ, Joshua C, Zohoori N, Porter A 3rd, Slagle D, Dillaha J. Vaccine. 2025 Oct 15;66:127834. doi: 10.1016/j.vaccine.2025.127834. Online ahead of print. PMID: 41106171

Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 **vaccine** development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults.
Caraco Y, Madar-Balakirski N, Ben-Ami E, Zeltser D, Maayan S, Eliakim-Raz N, Peer A, Brosh-Nissimov T, Vishlitzky V, Beth-Din A, Bar-Haim E, Israely T, Paran N, Fisher M, Hoggeg M, Atsmon J, Cohen D, Goldstaub D, Levin Y, Danon Y, Panet A, Shapira S, Yitzhaki S, Marcus H. Vaccine. 2025 Oct 16;67:127837. doi: 10.1016/j.vaccine.2025.127837. Online ahead of print. PMID: 41106035

Impact of the COVID-19 Pandemic on Routine Childhood Vaccination Coverage in Ecuador From 2019 to 2021: Comparative Analysis.
Sanchez J, Rodriguez AA Sr, Cuello KPM Sr. JMIRx Med. 2025 Oct 17;6:e75293. doi: 10.2196/75293. PMID: 41105965 Free PMC article.

Simultaneous induction of multiple classes of broadly neutralizing antibody precursors by combination germline-targeting immunization in nonhuman primates.
Sutton HJ, Ma KM, Steichen JM, Schiffner T, Altheide TK, Liguori A, Lu D, Kubitz M, Georgeson E, Phelps N, Tingle R, Alavi NB, Ben-Akiva E, Zhou X, Kifude C, Flynn CT, Rakasz E, Irvine DJ, Schief WR, Crotty S. Sci Immunol. 2025 Oct 17;10(112):eadu8878. doi: 10.1126/sciimmunol.adu8878. Epub 2025 Oct 17. PMID: 41105754

Simultaneous priming of HIV broadly neutralizing antibody precursors to multiple epitopes by germline-targeting mRNA-LNP immunogens in mouse models.
Xie Z, Wang X, Yan Y, Steichen JM, Ma KM, Cottrell CA, Melzi E, Bottermann M, Villavicencio PM, Rantalainen K, Schiffner T, Warner JE, Weldon SR, Prum T, Ellis-Pugh JR, Torres JL, Jackson AM, Flynn CT, Ozorowski G, Himansu S, Carfi A, Ward AB, Nair U, Schief WR, Batista FD. Sci Immunol. 2025 Oct 17;10(112):eadu7961. doi: 10.1126/sciimmunol.adu7961. Epub 2025 Oct 17. PMID: 41105753

Coronavirus Disease 2019 (COVID-19) Vaccination Coverage and Effectiveness Among Pediatric Transplant Recipients.
Cohen E, Hinderstein S, Carciofi E, Hopkins K, Kuzaro H, Yildirim I. Prog Transplant. 2025 Oct 17:15269248251383951. doi: 10.1177/15269248251383951. Online ahead of print. PMID: 41105146

Viral detection in children less than 5 years with bronchiolitis, pneumonia, and croup, New **Vaccine** Surveillance Network, 2017-2023.
Teoh Z, Toepfer AP, Rohlfs C, Harrison CJ, Klein EJ, Schlaudecker EP, Weinberg GA, Englund JA, Williams JV, Boom JA, Sahni LC, Michaels MG, Halasa N, Stewart LS, Szilagyi PG, Selvarangan R, McMorrow ML, Moline H, Staat MA. J Pediatric Infect Dis Soc. 2025 Oct 17:piaf096. doi: 10.1093/jpids/piaf096. Online ahead of print. PMID: 41105105

Measles Resurgence and the Fragility of Herd Immunity: Implications for Pediatric Infectious Disease Practice.
Hijano DR, Oresntein WA, Oliveira CR. J Pediatric Infect Dis Soc. 2025 Oct 17:piaf094. doi: 10.1093/jpids/piaf094. Online ahead of print. PMID: 41105102

Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination.
AlZeera AJ, Qamber MA, AlZeera JA. Cureus. 2025 Oct 13;17(10):e94483. doi: 10.7759/cureus.94483. eCollection 2025 Oct. PMID: 41104031 Free PMC article.

Effectiveness of the autumnal COVID-19 **vaccine** dose during the winter and summer waves of the 2023/24 season in Spain.
Rojas-Benedicto A, Pérez-Gimeno G, Mendioroz J, Pedrosa Corral I, López Torrijos M, Rumayor M, Rafael de la Cruz Lopez MA, Rivas Wagner E, Valcárcel de Laiglesia M, Guiu Cañete I, Fernández Ibañez A, Pérez Martínez O, Linares Dópido JA, Latasa P, Torres-Juan M, Rodríguez Recio MJ, Castrillejo D, Viloria Raymundo LJ, López Berrios N, Vázquez-Morón S, Monge S, SiVira. Expert Rev Vaccines. 2025 Oct 17. doi: 10.1080/14760584.2025.2576243. Online ahead of print. PMID: 41103179 Free article.

Maternal influenza vaccination intention and associated factors among pregnant women in Guizhou Province, China.
Jiang F, Qu B, Gao Y, Feng J, Tang N, Ye X. Hum Vaccin Immunother. 2025 Dec;21(1):2575651. doi: 10.1080/21645515.2025.2575651. Epub 2025 Oct 17. PMID: 41103146 Free article.

Birth order and influenza vaccination: a comparative study of behaviors and intentions between first-time and second-time Chinese parents.
Chen K, Xu Z, Zhou Y, Chu L, Wang H, Fu C. Expert Rev Vaccines. 2025 Dec;24(1):972-979. doi: 10.1080/14760584.2025.2576235. Epub 2025 Oct 21. PMID: 41103076 Free article.

Extracellular Vesicles are Key Mediators for Direct Antigen Transport to Draining Lymph Nodes.
Wang C, Cheng X, Cheng K, Yuan F. Mol Ther. 2025 Oct 16:S1525-0016(25)00855-X. doi: 10.1016/j.ymthe.2025.10.034. Online ahead of print. PMID: 41103032

Bioinformatic Design of the Secreted form of SAG2 Protein as a Toxoplasma gondii **Vaccine** Candidate.
Mesri A, Asadi N, Maleki-Kakelar H, Taheri-Anganeh M. Recent Pat Biotechnol. 2025 Oct 14. doi: 10.2174/0118722083412016250925074449. Online ahead of print. PMID: 41102957

Absolute and Relative Effectiveness of Cell- and Egg-based Quadrivalent Inactivated Influenza **Vaccine** Products from 2014-2015 to 2018-2019 seasons, U.S. Flu VE Network.
Gaglani M, Raiyani C, Murthy K, Smith M, da Graca B, Dubrocq G, Beeram M, Martin ET, Monto AS, Zimmerman RK, Nowalk MP, Kiniry E, Phillips CH, Nguyen HQ, King JP, Kim SS, Chung JR, Flannery B. Clin Infect Dis. 2025 Oct 16:ciaf579. doi: 10.1093/cid/ciaf579. Online ahead of print. PMID: 41102880

Adolescent literacy, trust, and acceptance of vaccines before and after educational intervention: protocol for a mixed methods research.
de Freitas BHBM, Lima JC, Sartori AL, Haeffner R, Nemer CRB, da Silva ARV, Sales CMM, Garcia EM, Bortolini J, Ratzan SC. BMC Public Health. 2025 Oct 16;25(1):3511. doi: 10.1186/s12889-025-24311-w. PMID: 41102703 Free PMC article.

Self-reported poliomyelitis vaccination and documentation in adults indicates high uptake: a digital German epidemic panel, December 2024.
Kettlitz R, Harries M, Contreras S, Reinecke J, Wieder MS, von Lengerke T, Castell S, Lange B, Klett-Tammen CJ; PCR-4-ALL study group; MuSPAD study group. BMC Public Health. 2025 Oct 16;25(1):3514. doi: 10.1186/s12889-025-24865-9. PMID: 41102690 Free PMC article.

Availability and readiness of healthcare services at primary healthcare centers during the Sudan war: a cross-sectional study.
Rabih M, Ahmed ABM, Abdelgyoum HA, Elhassan S, Mohamed EEA, Yasin FMO, Fadlalmoula GAAGA, Arbab M, Salih MAM, Ahmed RAA, Ahmed MBM. BMC Prim Care. 2025 Oct 16;26(1):317. doi: 10.1186/s12875-025-03015-5. PMID: 41102632 Free PMC article.

Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and/or reactivation antigen RpfE.
Ashayeripanah M, Kazemi B, Saubi N, Joseph-Munne J, Eftekhar F. BMC Infect Dis. 2025 Oct 16;25(1):1338. doi: 10.1186/s12879-025-11534-w. PMID: 41102630 Free PMC article.

Cancer vaccines as enablers of immunotherapy.
Khleif SN, Gupta S. Nat Immunol. 2025 Oct 16. doi: 10.1038/s41590-025-02308-2. Online ahead of print. PMID: 41102462

Enhancing explainability in epidemiological predictions using fuzzy logic integrated with machine and deep learning algorithms.
Fatima U, Khushal R. Sci Rep. 2025 Oct 16;15(1):36139. doi: 10.1038/s41598-025-10689-5. PMID: 41102270 Free PMC article.

A replicating RNA **vaccine** protects against severe fever with thrombocytopenia syndrome virus infection in mice.
Stamper A, Bisom T, Meade-White K, Lewis M, Leventhal S, Clancy C, Hinkley T, Erasmus J, Feldmann H, Hawman DW. NPJ Vaccines. 2025 Oct 16;10(1):219. doi: 10.1038/s41541-025-01269-9. PMID: 41102248 Free PMC article.

Ultrapotent human antibodies lock E protein dimers central region of diverse DENV3 morphological variants.
Fibriansah G, Ng TS, Lim XN, Shebanova A, Ng LC, Tan SL, Tan AWK, Shi J, Crowe JE Jr, Lok SM. Nat Commun. 2025 Oct 16;16(1):9182. doi: 10.1038/s41467-025-64210-7. PMID: 41102151 Free PMC article.

Montanide ISA-51: a promising adjuvant in cancer **vaccine** immunotherapy.
Nan L, Zhang X, Ziyi L, Li S, Xia N. Expert Rev Vaccines. 2025 Oct 16. doi: 10.1080/14760584.2025.2576234. Online ahead of print. PMID: 41102132 Free article. Review.

A radical approach to improving **vaccine** uptake.
Yang YT. BMJ. 2025 Oct 16;391:r2159. doi: 10.1136/bmj.r2159. PMID: 41101986

Nurses' Perspectives on Caring for Critically Ill Children During a Measles Outbreak: A Case Report.
Gallegos C, Robinson M, Ayola B, Kovar L, Roehrig N. Crit Care Nurse. 2025 Oct 17:e1-e7. doi: 10.4037/ccn2025966. Online ahead of print. PMID: 41101776

Elastin-like peptides for efficient and safe delivery of mRNA.
Li F, Wang Q, Wang T, Xiong C, Chen Z, Ouyang H, Lou X, Xia F, Wang S, Wu M, Dai J. J Control Release. 2025 Oct 14;388(Pt 1):114337. doi: 10.1016/j.jconrel.2025.114337. Online ahead of print. PMID: 41101699

Composition, stabilization and delivery of virus-based vaccines: considerations to break free of the cold chain.
Epoh AJ, Doyle JH, Bajrovic I, Croyle MA. Adv Drug Deliv Rev. 2025 Oct 14:115715. doi: 10.1016/j.addr.2025.115715. Online ahead of print. PMID: 41101694 Free article.

TUBERCULOSIS AND INFLAMMATORY BOWEL DISEASE.
Madero L, Bastón I, Brunet-Mas E, Calafat M; Grupo Joven de GETECCU. Gastroenterol Hepatol. 2025 Oct 14:502587. doi: 10.1016/j.gastrohep.2025.502587. Online ahead of print. PMID: 41101460

Innovative therapeutic cancer **vaccine** PDC()lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.
Vansteenkiste J, Demedts I, Cuppens K, Pons-Tostivint E, Wauters E, Borm FJ, Sibille A, Colinet B, Pérol M, Theelen WSME, Biesma B, Van De Kerkhove C, Buchmeier E, Althoff FC, Derijcke S, Moro-Sibilot D, Laulagnier K, Halioua E, Levy L, Genin M, Michel S, Dedry C, Duchayne C, Collodoro M, Renard F, Adriaenssens S, De Vos B, Cantero F, Plumas J, Skrzypski M. ESMO Open. 2025 Oct 14;10(11):105844. doi: 10.1016/j.esmoop.2025.105844. Online ahead of print. PMID: 41101155 Free article.

A statistical method for evaluating **vaccine**-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.
Williams LR, Voysey M, Pollard AJ, Grassly NC. Vaccine. 2025 Oct 15;67:127856. doi: 10.1016/j.vaccine.2025.127856. Online ahead of print. PMID: 41101087 Free article.

Strategies for addressing COVID-19 **vaccine** equity with intermediaries, prevention research centers, and the **vaccine** confidence network.
Hara-Hubbard KK, Beaulieu A, Mendiola A, Gandhi P, Kuiper N, Quartarone R, Tang J, Dominguez O, Bond M, Cohen D, Goetz M, Mohamed N, Cuccaro P, Hannon PA, Fernandez ME, Higginbottom J, Pérez-Escamilla R, Baquero B. Vaccine. 2025 Oct 15;60 Suppl 1:127847. doi: 10.1016/j.vaccine.2025.127847. Online ahead of print. PMID: 41101080

Temporal Trends in Cervical Human Papillomavirus Prevalence Among Females in Xiamen, China (2016-2023): Cross-Sectional Study.
Chen Z, Lin E, Chen M, Wang S, Lin Q, Chen Q, Xue H, Zhang G. JMIR Public Health Surveill. 2025 Oct 16;11:e70507. doi: 10.2196/70507. PMID: 41100857 Free PMC article.

Mechanisms of Norovirus Immunity: Implications for **Vaccine** Design.
Ökten AB, Craft JE, Wilen CB. Annu Rev Pathol. 2025 Oct 16. doi: 10.1146/annurev-pathmechdis-042524-021922. Online ahead of print. PMID: 41100711

Integration of mathematical modeling and economics approaches to evaluate strategies for control of Salmonella Dublin in a heifer-raising operation.
Llanos-Soto S, Wiedmann M, Adalja A, Henry C, Moroni P, Frye E, Leal Yepes FA, Ivanek R. PLoS One. 2025 Oct 16;20(10):e0332465. doi: 10.1371/journal.pone.0332465. eCollection 2025. PMID: 41100510 Free PMC article.

Differences in immunogenicity to zoster recombinant **vaccine** in IMID patients undergoing treatment with non-selective or selective JAK-i.
Sieiro-Santos C, Herrero JG, Ordas Martínez J, Álvarez Castro C, López Robles A, Colindres R, Sierra Ausin M, Martín ER, Sahagun AM, Ruiz de Morales JG. Rheumatology (Oxford). 2025 Oct 16:keaf533. doi: 10.1093/rheumatology/keaf533. Online ahead of print. PMID: 41100077

The silent spread of Hepatitis E in India - from epidemiological insight to public health action: a comprehensive review.
Maity S, Chowdhary S, Swaminathan A, Ashtaputre N, Mudgal PP, Mukhopadhyay C. Infection. 2025 Oct 16. doi: 10.1007/s15010-025-02661-2. Online ahead of print. PMID: 41100012

Epidemiology and Clinical Profile of Intussusception in Children Aged Under 2 Years in Maharashtra, India.
Haseeb M, Deshpande V, Ali SY, Engade M, Parelkar S, Makhija D, Kothari P, Deshmukh S, Bavdekar A, Bora A, Jadhav S, Ganguli A, Dihare T, Nagdeve N, Chaudhary VS, Kharat N, Machathi A, Lingam R. Indian J Pediatr. 2025 Oct 16. doi: 10.1007/s12098-025-05777-3. Online ahead of print. PMID: 41099965

"It really is HPV that's pulling us down": Findings from a health plan quality improvement learning collaborative targeting the HEDIS IMA measure.
Foley S, Flowers A, Isher-Witt J, Crawford K, Nkonga J, Burcin M, Gaglioti AH. Hum Vaccin Immunother. 2025 Dec;21(1):2569760. doi: 10.1080/21645515.2025.2569760. Epub 2025 Oct 16. PMID: 41099725 Free PMC article.

HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results.
Hernández-Bernal F, Bernal KS, Bequet-Romero M, Martín-Bauta Y, Catasús-Álvarez KM, Carreño-Rolando IE, Rodríguez-Reinoso JL, Madrigal YLJ, González SML, Debora-Morales Y, Alonso-Valdés M, Chávez-Chong CO, Lemos-Pérez G, de la Iglesia MP, Limonta-Fernández M, Muzio-González VL, Ayala-Ávila M, Morera-Díaz Y; CENTAURO-4 Group of Investigators. Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70199. Online ahead of print. PMID: 41099583

Understanding public confidence in locally-produced mRNA vaccines: Insights for future pandemic preparedness.
Wong LP, Alias H, Lee HY. Hum Vaccin Immunother. 2025 Dec;21(1):2573562. doi: 10.1080/21645515.2025.2573562. Epub 2025 Oct 16. PMID: 41099205 Free PMC article.

Recombinant *Mycobacterium smegmatis* expressing antigen 85B for immunotherapy of *Mycobacterium tuberculosis*-infected mice.
Chang Y, Ning H, Liang X, Lu Y, Kang J, Li X, Liu S, Hao L, Ma Y, Zhang F, Bai Y. Hum Vaccin Immunother. 2025 Dec;21(1):2571287. doi: 10.1080/21645515.2025.2571287. Epub 2025 Oct 16. PMID: 41099192

Developing accessible and affordable tests to support mpox immunosurveillance and **vaccine** studies.
Faustini SE, Jones S, Green CA, Otter AD, Richter AG, Heaney JL. Emerg Microbes Infect. 2025 Oct 16:2576581. doi: 10.1080/22221751.2025.2576581. Online ahead of print. PMID: 41099136 Free article.

Development of a broad-spectrum nasal live attenuated influenza **vaccine** based on mosaic antigen design against influenza B viruses.
Han X, Ma R, Ma X, Chen H, Zhao T, Liu X, Zhu L, Yuan L, Shi Y, Zhang Y, Yang Z, Chen Q, Lu J, Chen C, Pang W, Bai T, Zhu W, Shu Y. Emerg Microbes Infect. 2025 Oct 15:2576141. doi: 10.1080/22221751.2025.2576141. Online ahead of print. PMID: 41097933 Free article.

Nanomotor-Promoted In Situ Vaccination for Deep-Seated Cancer Immunotherapy.
Song A, Yuan H, Wang W, Ji Y, Zhang Y, Ren J, Qu X. ACS Nano. 2025 Oct 15. doi: 10.1021/acsnano.5c11038. Online ahead of print. PMID: 41097929

Influenza **vaccine** uptake in juvenile idiopathic arthritis during the COVID-19 pandemic: a multi-centre cross-sectional study by PRES vaccination working party.
Maritsi D, Alpert N, Bizjak M, Ziv A, Balaziova B, Yildiz M, Gagro A, Sestan M, Khabirova A, Sozeri B, Caglayan S, Jelusic M, Opoka-Winiarska V, Kostik M, Bracaglia C, Minoia F, Dallos T, Kasapcopur O, Toplak N, Uziel Y, Tsagkli P, Heshin-Bekenstein M. Pediatr Rheumatol Online J. 2025 Oct 15;23(1):103. doi: 10.1186/s12969-025-01158-4. PMID: 41094677 Free PMC article.

Determinants of mpox vaccination uptake among MSM during the 2022 outbreak: a single-centre retrospective study at Lyon University Hospital, France.
Merad Y, Godinot M, Alfaiate D, Becker A, Ader F, Cotte L, Conrad A. BMC Public Health. 2025 Oct 15;25(1):3496. doi: 10.1186/s12889-025-24728-3. PMID: 41094414 Free PMC article.

Influenza **vaccine** based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates.
Akhtar A, Styles TM, Gu C, León AN, Tharp GK, Stokdyk K, Abbad A, Hirst C, Strohmeier S, Neumann G, Richey ST, Ferguson JA, Mala U, Ahmed H, Han J, Carreño JM, Davis CW, Antia R, Palese P, Ward AB, Kawaoka Y, Krammer F, Ahmed R, Amara RR. Nat Immunol. 2025 Oct 15. doi: 10.1038/s41590-025-02309-1. Online ahead of print. PMID: 41094203

A **vaccine** central in A(H5) influenza antigenic space confers broad immunity.
Kok A, Wilks SH, Tureli S, James SL, Bestebroer TM, Burke DF, Funk M, van der Vliet S, Spronken MI, Rijnink WF, Pattinson DJ, de Meulder D, Rosu ME, Lexmond P, van den Brand JMA, Herfst S, Smith DJ, Fouchier RAM, Richard M. Nature. 2025 Oct 15. doi: 10.1038/s41586-025-09626-3. Online ahead of print. PMID: 41094140

New bird flu **vaccine** could tackle multiple variants with one shot.
Thompson B, Bundell S. Nature. 2025 Oct 15. doi: 10.1038/d41586-025-03383-z. Online ahead of print. PMID: 41094053

Rotavirus **vaccine** reduces gastroenteritis hospitalizations in Indian children.
[No authors listed] Nat Med. 2025 Oct 15. doi: 10.1038/s41591-025-04034-6. Online ahead of print. PMID: 41094035

Explaining Twitter's inability to effectively moderate content during the COVID-19 pandemic.
Broniatowski DA, Zhong W, Simons JR, Jamison AM, Dredze M, Abroms LC. Sci Rep. 2025 Oct 15;15(1):36096. doi: 10.1038/s41598-025-20033-6. PMID: 41093931 Free PMC article.

Reply to "Broadening the perspective on mpox: addressing inequities, surveillance gaps, and long-term challenges".
Chen CY, Lin YC, Fang CT. J Formos Med Assoc. 2025 Oct 14:S0929-6646(25)00555-8. doi: 10.1016/j.jfma.2025.10.011. Online ahead of print. PMID: 41093692 Free article.

Adverse Events After Measles and Bacillus Calmette-Guérin Vaccinations of Women of Fertile Age in Guinea-Bissau. A Nested Study Within an Open-Label Placebo-Controlled Randomised Trial.
Silva I, Nielsen S, Aaby P, Benn CS, Schaltz-Buchholzer F. Trop Med Int Health. 2025 Oct 15. doi: 10.1111/tmi.70052. Online ahead of print. PMID: 41093663

US **vaccine** misinformation is having "frightening" ripple effect in Europe, leaders warn.
Mahase E. BMJ. 2025 Oct 15;391:r2167. doi: 10.1136/bmj.r2167. PMID: 41093601

Evaluating the impact of unadjusted confounding and study design on estimated pathogen-attributable diarrhea incidence among children in the MAL-ED cohort.
Doran CR, Platts-Mills JA, Houpt E, Liu J, McQuade ETR. J Infect Dis. 2025 Oct 16:jiaf531. doi: 10.1093/infdis/jiaf531. Online ahead of print. PMID: 41093286

Nanotechnology-based delivery strategies for drugs and vaccines targeting blood stage malaria: A systematic review.
Amos Y, Rubaka C, Sauli E, Swai H, Tumbo A. Nanomedicine. 2025 Oct 13:102869. doi: 10.1016/j.nano.2025.102869. Online ahead of print. PMID: 41093261

Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies.
Yegorov S, Patel OD, Sharma H, Khan T, Gupta R, Yao M, Sritharan A, Silverman N, Pullenayegum E, Miller MS, Loeb M. Clin Microbiol Infect. 2025 Oct 13:S1198-743X(25)00474-4. doi: 10.1016/j.cmi.2025.09.023. Online ahead of print. PMID: 41093140 Free article.

Experimental production of synthetic infectious porcine circovirus 2b particles in swine testicular cells.
Vieira LB, da Cruz TF, da Silva BL, de Paiva Pereira K, Junior JPA, Magro AJ. J Virol Methods. 2025 Oct 13;340:115280. doi: 10.1016/j.jviromet.2025.115280. Online ahead of print. PMID: 41092982

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Causes of Death Collaborators. Lancet. 2025 Oct 18;406(10513):1811-1872. doi: 10.1016/S0140-6736(25)01917-8. Epub 2025 Oct 12. PMID: 41092928 Free PMC article.

Primate resident memory T cells activate humoral and stromal immunity.
Joag V, Bimber BN, Quarnstrom CF, Bollimpelli VS, Schenkel JM, Fraser KA, Bertogliat M, Soerens AG, Stolley JM, O'Flanagan SD, Rosato PC, Gavil NV, Künzli M, Mitchell JS, Legere T, Jean S, Upadhyay AA, Kang CY, Gibbs J, Yewdell JW, Fife BT, Park H, Hansen SG, Bosinger SE, Barber GN, Skinner PJ, Vezys V, Hunter E, Picker LJ, Amara RR, Masopust D. Immunity. 2025 Oct 14;58(10):2541-2555.e6. doi: 10.1016/j.immuni.2025.09.009. PMID: 41092897

Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue **vaccine**.
Peixoto de Miranda ÉJF, de Sousa Moreira JA, da Silva Braga R, Silveira DHR, Infante V, de Oliveira Alves LB, de Camargo Vieira Tenorio J, Dos Santos Silva GF, Patiño EG, de Mesquita Pacheco PHT, Ramos F, Oliveira DS, Kallás EG, Boulos FC. Vaccine. 2025 Oct 14;66:127836. doi: 10.1016/j.vaccine.2025.127836. Online ahead of print. PMID: 41092804

Hepatitis B virus infection and **vaccine** coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
Collins C, Ratshisusu L, Modise LM, Simani OE, Selabe SG, Muloiwa R, Copelyn J, Amponsah-Dacosta E. Vaccine. 2025 Oct 14;66:127843. doi: 10.1016/j.vaccine.2025.127843. Online ahead of print. PMID: 41092803 Free article.

Advancing typhoid conjugate **vaccine** implementation in Asia: Regional policy priorities.
Carter AS, Steele D, John J, Saha S, Laurens MB, Minta AA, Volavola L, Moedjito I, Phounphenghack K, Mahat D, Nyein SL, Gautam A, Sespeñe MFVS, Pati T, Huong NTT, Gupta N, George LS, Jayaprakasam M, Gupta A, Garrett DO. Vaccine. 2025 Oct 14;66:127848. doi: 10.1016/j.vaccine.2025.127848. Online ahead of print. PMID: 41092802 Free article.

Genome sequence of the Myxoma virus Borghi **vaccine** strain.
Bazzucchi M, Rossini E, Cavadini P, Bertasio C, Lavazza A. Vaccine. 2025 Oct 14;66:127835. doi: 10.1016/j.vaccine.2025.127835. Online ahead of print. PMID: 41092801 Free article.

TCR bias drives development of dominant **vaccine**-induced CD8+ T cell responses which can be redirected toward cellular targets.
Iversen EF, Rahimic AHF, Frattari GS, Rosás-Umbert M, Schleimann MH, Olesen R, Gunst JD, Søgaard OS, Krogsgaard M, Tolstrup M. Vaccine. 2025 Oct 14;66:127851. doi: 10.1016/j.vaccine.2025.127851. Online ahead of print. PMID: 41092800 Free article.

Corrigendum to "Development of African horse sickness disabled infectious single animal (DISA)-DIVA **vaccine** platform applied for all nine serotypes" [**Vaccine** 64 (2025) 127772].
van Rijn PA, Wernery U, Feddema AJ, Maris-Veldhuis MA, Joseph S, van Gennip RGP. Vaccine. 2025 Oct 14;66:127839. doi: 10.1016/j.vaccine.2025.127839. Online ahead of print. PMID: 41092799 Free article.

COVID-19 **Vaccine** Effectiveness in Patients with Hematologic Malignancies: a Nationwide Cohort Study.
Hofsink Q, Lissenberg-Witte BI, Haggenburg S, Goorhuis A, Hazenberg MD, Rutten CE, den Tex P, de Vries EGE, van der Veldt AAM, Kemmeren JM, de Keizer NF, Huijgens PC, Dinmohamed AG, van Roon A, Pijpers J, van Roekel C, van den Hof S, Hahné SJM, de Gier B, Heijmans J, Nijhof IS. J Infect Dis. 2025 Oct 14:jiaf523. doi: 10.1093/infdis/jiaf523. Online ahead of print. PMID: 41092195

Evaluating Large Language Models for Sentiment Analysis and Hesitancy Analysis on **Vaccine** Posts From Social Media: Qualitative Study.
Annan A, Eiden AL, Wang D, Du J, Rastegar-Mojarad M, Nomula VK, Wang X. JMIR Form Res. 2025 Oct 15;9:e64723. doi: 10.2196/64723. PMID: 41092067 Free PMC article.

Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice.
Hendricks GG, Grigoryan L, Navarro MJ, Catanzaro NJ, Hubbard ML, Powers JM, Mattocks M, Treichel C, Walls AC, Lee J, Ellis D, Wang JYJ, Cheng S, Miranda MC, Valdez A, Chao CW, Chan S, Men C, Johnson MR, Zepeda SK, Ols S, Hui H, Wu SY, Lujan V, Muramatsu H, Lin PJC, Sung MMH, Tam YK, Leaf EM, Pardi N, Baric RS, Pulendran B, Veesler D, Schäfer A, King NP. Sci Transl Med. 2025 Oct 15;17(820):eadu2085. doi: 10.1126/scitranslmed.adu2085. Epub 2025 Oct 15. PMID: 41091918

An intramuscular prime and mucosal boost **vaccine** regimen protects against lethal clade 2.3.4.4b H5N1 challenge in cynomolgus macaques.
Lasrado N, Wang L, Liu J, Rössler A, Chaudhari J, Wang Q, Stone JJ, Granados-Contreras FA, Wu J, Cabrera-Barragan DN, Waller-Pulido A, Nangle SJ, Shah K, Boduch R, Warke S, Cook A, Kitajewski C, Pessaint L, Lewis MG, Andersen H, Martinot AJ, McNamara RP, Barouch DH. Sci Transl Med. 2025 Oct 15;17(820):eady2282. doi: 10.1126/scitranslmed.ady2282. Epub 2025 Oct 15. PMID: 41091914

More work for ASHAs? Exploring the role of whatsapp messaging and community health work in urban slum areas of Varanasi, India.
Jamison A, Ganjoo R, Tharmarajah SN, Panda BK, Parida M, Pandey S, Pandey M, Mohanty S, Rimal RN. PLOS Glob Public Health. 2025 Oct 15;5(10):e0005157. doi: 10.1371/journal.pgph.0005157. eCollection 2025. PMID: 41091739 Free PMC article.

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants.
Mellis IA, Wu M, Hong H, Tzang CC, Bowen A, Wang Q, Gherasim C, Pierce VM, Shah JG, Purpura LJ, Yin MT, Gordon A, Guo Y, Ho DD. Cell Rep. 2025 Oct 14;44(10):116440. doi: 10.1016/j.celrep.2025.116440. Online ahead of print. PMID: 41091599 Free article.

Effectiveness and impact of 7 and 13-valent pneumococcal conjugate vaccines in Chinese children: A systematic review and meta-analysis.
Peng R, Zhang T, Dunne EM, Xu Z, Sun A, Cheng J, Yang J, Zhao G. Hum Vaccin Immunother. 2025 Dec;21(1):2573542. doi: 10.1080/21645515.2025.2573542. Epub 2025 Oct 15. PMID: 41091551 Free PMC article.

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
Yuile A, Wei JQ, McKelvey KJ, Colvin EK, Zakarya R, Stoner SP, Jagadeesan A, Yunus M, de Silva HC, Gilson J, Leck L, Arzuman L, Zhang O, Oatley M, Pavlakis N, Chan DI, Itchins M, Kastelan M, Lee A,

Wheeler HR, Menzies A, Diakos CI, Guminski A, Back M, Eade T, Jayamanne D, Kneebone A, Hudson AL. J Neurooncol. 2025 Oct 15;176(1):10. doi: 10.1007/s11060-025-05258-9. PMID: 41091287 Free PMC article.

Assessing the Impact of Routine and Campaign Vaccination on Measles Transmission: A Modeling Study.
Sinigirira KJG, Peter OJ, Balogun GB, Bolarin G. Acta Biotheor. 2025 Oct 15;73(4):16. doi: 10.1007/s10441-025-09507-2. PMID: 41091216

Factors associated with willingness to accept pneumococcal **vaccine** based on the Health Belief Model among the elderly (60 years) living in Klang Valley, Malaysia.
Mohd Hisham MF, Sreeramareddy CT. Hum Vaccin Immunother. 2025 Dec;21(1):2573519. doi: 10.1080/21645515.2025.2573519. Epub 2025 Oct 15. PMID: 41091121 Free PMC article.

Summary of final data from the 9-valent human papillomavirus **vaccine** pregnancy registry (2014-2021).
Hardalo C, Marko A, Sciba B, Rausch D, Sieger B, Leong R, Tota JE, Luxembourg A, Kaplan SS. Hum Vaccin Immunother. 2025 Dec;21(1):2569749. doi: 10.1080/21645515.2025.2569749. Epub 2025 Oct 15. PMID: 41091019 Free PMC article.

SARS-CoV-2 breakthrough infections in a retrospective cohort of vaccinated university students and employees.
Lemos JRN, Suarez M, Thomas S, Alvarez Canedo JC, Gangadhara A, Reis DW, Weiss RE. Hum Vaccin Immunother. 2025 Dec;21(1):2572849. doi: 10.1080/21645515.2025.2572849. Epub 2025 Oct 15. PMID: 41090672 Free PMC article.

Knowledge, attitudes, and practices regarding HPV infection, cervical cancer, and HPV vaccination among Emirati women.
Sozib SI, Smail L, Jassim GA. Future Oncol. 2025 Oct 15:1-11. doi: 10.1080/14796694.2025.2575519. Online ahead of print. PMID: 41090532

Legal questions of AI-generated immunological products for infectious diseases.
Zumárraga J, McConnell MJ, López D, Martín-Galiano AJ. Hum Vaccin Immunother. 2025 Dec;21(1):2570962. doi: 10.1080/21645515.2025.2570962. Epub 2025 Oct 15. PMID: 41090374 Free PMC article.

Acceptability of patient-centered digital **vaccine** safety monitoring: A Canadian Immunization Research Network study.
Ellis-Legault B, Wilson K, Greyson D, Shulha HP, Nilormi A, Bettinger JA. Hum Vaccin Immunother. 2025 Dec;21(1):2571277. doi: 10.1080/21645515.2025.2571277. Epub 2025 Oct 14. PMID: 41088802 Free PMC article.

Temporally integrated multiomics analysis elucidates intricate regulatory mechanisms of ASFV in a wild boar lung-derived clonal cell line.
Wang H, Ye M, Weng W, Wu J, Qu Y, Gao P, Zhang Y, Zhou L, Ge X, Guo X, Han J, Yang H. Vet Res. 2025 Oct 14;56(1):193. doi: 10.1186/s13567-025-01629-2. PMID: 41088433 Free PMC article.

Measles and public health: an integrative approach.
Branda F, Giovanetti M, Petrosillo N, Ahmed MM, Perra M, Sanna D, Ceccarelli G, Ciccozzi M, Bucci E, Scarpa F. Biol Direct. 2025 Oct 14;20(1):103. doi: 10.1186/s13062-025-00693-0. PMID: 41088248 Free PMC article.

Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system.
Meng C, Zhang H, Yi X, Kong G, Zhang X, Wang B, Xu Y, Qi H, Wu Q, Zhang K, Cao J, Lin X, Feng H, Chen J, Zheng S, Gu Z, Li H, Ling Q. Mol Cancer. 2025 Oct 14;24(1):258. doi: 10.1186/s12943-025-02480-x. PMID: 41088223 Free PMC article.

POST introduction evaluation (PIE) of the malaria **vaccine** introduced in three pilot countries (Ghana, Kenya, and Malawi) in 2021.
Walldorf JA, Mayers GF, Amponsa-Achiano K, Jalang'o R, Chisema M, Khalayi L, Njoroge J, Haji A, Tweneboah PO, Sally ET, Mategula D, Mhone B, Zimba B, Chirwa E, Mohammed NT, Adjei MR, Sillah J, Pellaux-Furrer E, Magafu MGMD, Okine RNA. Malar J. 2025 Oct 14;24(1):333. doi: 10.1186/s12936-025-05590-5. PMID: 41088219 Free PMC article.

Ensemble techniques for predictive modeling of leishmanial activity via molecular fingerprints.
Nalband S, Kiratkar P, Gupta M, Gambhir M, Sonam S, Robert F, Prince AA. BMC Med Inform Decis Mak. 2025 Oct 14;25(1):378. doi: 10.1186/s12911-025-03041-4. PMID: 41088199 Free PMC article.

Viral co-infections in pediatric acute gastroenteritis: epidemiology of rotavirus, norovirus, adenovirus, and astrovirus in Tehran, Iran (2021-2022).
Kachooei A, Ataei-Pirkooh A, Mir-Hosseinian M, Behnezhad F, Eftekhari M, Hoseini-Fakhr SS, Jalilvand S, Latifi T, Khouy RA, Shoja Z. BMC Infect Dis. 2025 Oct 14;25(1):1319. doi: 10.1186/s12879-025-11668-x. PMID: 41088042 Free PMC article.

Association between vaccination status and clinical characteristics among young adults infected with COVID-19.
Zhao W, Lu X, Yan Y, Xie L, Yan S. BMC Infect Dis. 2025 Oct 14;25(1):1321. doi: 10.1186/s12879-025-11652-5. PMID: 41087956 Free PMC article.

Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses.
Abu-Shmais AA, Freeman G, Creanga A, Vukovich MJ, Malla T, Mantus GE, Shimberg GD, Gillespie RA, Guerra Canedo V, Dadonaite B, Rodgers MD, Chopde AJ, Bardwil-Lugones E, Bylund T, Henry AR, Roberts-Torres J, Johnston TS, Smith S, Yang ES, Cheng C, Walker EL, Ravichandran M, Gordon IJ, Dittakavi TS, Reed DS, Pierson TC, Dropulic L, Bloom JD, Tsybovsky Y, Boritz EA, Douek DC, Zhou T, Kanekiyo M, Andrews SF. Nat Microbiol. 2025 Oct 14. doi: 10.1038/s41564-025-02137-x. Online ahead of print. PMID: 41087744

Mechanisms of maternal antibody interference with rotavirus vaccination.
Chandler TL, Woodyear S, Chen V, Lonergan TM, Baker N, Harcourt K, Clare S, Ahmed F, Caddy SL. EMBO J. 2025 Oct 14. doi: 10.1038/s44318-025-00582-2. Online ahead of print. PMID: 41087582 Free article.

A health and economic evaluation of the spatial spillover effect from measles resurgence.
Xie K, Marathe A, Thakur M, Chen J, Deng X, Vullikanti A. Sci Rep. 2025 Oct 14;15(1):35862. doi: 10.1038/s41598-025-21097-0. PMID: 41087576 Free PMC article.

An integrated structural and immunoinformatic approach to design a multi-epitope based **vaccine** against the foot-and-mouth disease virus.
Sahoo S, Lee HK, Shin D. Sci Rep. 2025 Oct 14;15(1):35911. doi: 10.1038/s41598-025-19826-6. PMID: 41087454 Free PMC article.

Clinical features and outcomes of viral respiratory infections in adults during the 2023-2024 winter season.
Rousogianni E, Perlepe G, Boutlas S, Rapti G, Gouta E, Mpaltopoulou E, Mpaltopoulos G, Papagiannis D, Exadaktylos A, Gourgoulianis KI, Rouka E. Sci Rep. 2025 Oct 14;15(1):35800. doi: 10.1038/s41598-025-19236-8. PMID: 41087438 Free PMC article.

A multi-disciplinary exploration of the press review of the Italian National Institute of Health during the COVID-19 pandemic.
Fiammenghi C, Ceretti E, Covolo L, Pelizzari N, Taranto MA, Penna L, Brunelli L, Brusaferro S, Gelatti U. Hum Vaccin Immunother. 2025 Dec;21(1):2567680. doi: 10.1080/21645515.2025.2567680. Epub 2025 Oct 14. PMID: 41087315 Free PMC article.

Primary Antibody Deficiency in Patients With Chronic Rhinosinusitis: A Call for Immunologic Evaluation Prior to Biologic Therapy.
Petersen AG, Zainali-Gill K, Larsen CS, Nielsen C, Ovesen T. Clin Otolaryngol. 2025 Oct 14. doi: 10.1111/coa.70045. Online ahead of print. PMID: 41087302

Evaluation of depressive symptoms, HIV vulnerability and oral PrEP use and adherence among adolescent girls and young women in Western Kenya: a cross-sectional study.
Ouma DC, Otieno G, Hemmady A, Wakhu M, Jepkemoi L, Harrington EK, Onono M, Bukusi EA, Graham S. BMJ Open. 2025 Oct 14;15(10):e100011. doi: 10.1136/bmjopen-2025-100011. PMID: 41087109 Free PMC article.

Measles seroprevalence by birth cohort across the lifespan: a population-based, cross-sectional serosurvey in British Columbia, Canada.
Kaweski SE, Separovic L, Ashfaq S, Chan YLE, Dalati H, Henry B, Reyes RC, Hiebert J, Skowronski DM. CMAJ. 2025 Oct 13;197(34):E1099-E1107. doi: 10.1503/cmaj.250788. PMID: 41087048 Free PMC article.

Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue.
Farsiu N, Zandi K, Rukerd MRZ, Charostad J, Bashash D, Ghafari S, Pardeshenas M, Shahri M, Mirkamali H, Hassandarvish P, Nakhaie M, AbuBakar S. Am J Trop Med Hyg. 2025 Oct 14:tpmd250049. doi: 10.4269/ajtmh.25-0049. Online ahead of print. PMID: 41086802

Protective efficacy of two novel Klebsiella pneumoniae **vaccine** antigens, LysM/BON and OMPP1, in a murine model.
Hou Y, Zarodkiewicz P, Cortázar JT, Stoner D, Tulauskas Z, Macori G, Valvano MA, Ingram R, McClean S. Vaccine. 2025 Oct 13;66:127844. doi: 10.1016/j.vaccine.2025.127844. Online ahead of print. PMID: 41086758

Reproduction of antibody levels following five distinct ChAdOx1 nCoV-19 **vaccine** regimens through virtual patient cohorts.
Xavier MP, Dos Santos RW, Lobosco M. Comput Biol Med. 2025 Oct 13;198(Pt A):111149. doi: 10.1016/j.compbiomed.2025.111149. Online ahead of print. PMID: 41086748

Humoral immune responses to the second dose of a COVID-19 mRNA **vaccine** in cancer patients undergoing treatment.
Dang CM, Kemp TJ, Roche N, Haynesworth K, Loftus SA, Borski BJ, El Bakouny Z, Labaki C, Lee GM, Trowbridge R, Strauss S, Hughes ME, Lin NU, Choueiri TK, Pinto LA. Hum Vaccin Immunother. 2025 Dec;21(1):2570963. doi: 10.1080/21645515.2025.2570963. Epub 2025 Oct 14. PMID: 41086374 Free PMC article.

Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan.
Chou HH, Chu PY, Wu YH, Feng C, Wang W, Sukarom I, Pavelyev A. PLoS One. 2025 Oct 14;20(10):e0333757. doi: 10.1371/journal.pone.0333757. eCollection 2025. PMID: 41086167 Free PMC article.

Vaccination Conversations on X in Spanish and Catalan: Qualitative Content Analysis.
Huguet-Feixa A, Ahmed W, Artigues-Barberà E, Sol J, Godoy P, Ortega Bravo M. JMIR Infodemiology. 2025 Oct 14;5:e67942. doi: 10.2196/67942. PMID: 41086003 Free article.

Clinical and Epidemiological Characteristics and Rotavirus Vaccination Status in Children Aged Under 2 Years Hospitalized with Intussusception in Kerala, India, 2019-2022: A Multicenter Observational Study.
Sreenivasan P, Namboodiripad A, Ainipully AM, Abdul CS, Joji P, Abraham MK, Soman AC, Thuruthiyath N, Puthenvariath JN, Gupta N, Abraham A, Chaudhary VS, Machathi A, Kharat N, Lingam R. Indian J Pediatr. 2025 Oct 14. doi: 10.1007/s12098-025-05757-7. Online ahead of print. PMID: 41085871

Informing decisions in light of parameter uncertainty - an economic evaluation of the adjuvanted recombinant herpes zoster **vaccine** in Sweden.
Nystrand C, Widgren K, Hao S, Heintz E, Sparring V. Eur J Health Econ. 2025 Oct 14. doi: 10.1007/s10198-025-01829-9. Online ahead of print. PMID: 41085856

Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and **Vaccine** Development: Bridging Translational and Platform Gaps for Enhanced Decision Making.
Van LM, Chen N, Miyazawa K, Zhang M, Landersdorfer CB, Kirkpatrick CM, Pennucci J, Finn P, Ward CK, Gao W. Clin Pharmacol Ther. 2025 Oct 14. doi: 10.1002/cpt.70085. Online ahead of print. PMID: 41085467

Recombinant *lactococcus lactis* expressing HPV-16 E6E7 dual antigens for potential cervical cancer treatment enhances dendritic cell vaccines efficacy.
Li Y, Wei X, Li Y. Future Microbiol. 2025 Oct 14:1-11. doi: 10.1080/17460913.2025.2567700. Online ahead of print. PMID: 41084861 Free article.

A Novel Heterologous Prime-boost Strategy Using RUTI **Vaccine** to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.
Buisan O, Servian P, Pedreño-Lopez S, Pagès J, Urrea V, Martínez R, Garcia E, Cardona PJ, Vilaplana C, Amat M, Areal J, Bellmunt J, Clotet B, Cabrera C. Eur Urol. 2025 Oct 14:S0302-2838(25)00505-6. doi: 10.1016/j.eururo.2025.08.014. Online ahead of print. PMID: 41084757 Free article.

Can cultural facemasks enhance public health communication? Testing a theory-grounded messaging approach.
Perach R, Kostyuk E, Husbands D, Bondaronek P. Psychol Health. 2025 Oct 13:1-27. doi: 10.1080/08870446.2025.2571596. Online ahead of print. PMID: 41084358 Free article.

Topological Learning Prediction of Virus-like Particle Stoichiometry and Stability.
Liu X, Huang X, Wei GW. Biophys J. 2025 Oct 13:S0006-3495(25)00664-2. doi: 10.1016/j.bpj.2025.10.013. Online ahead of print. PMID: 41084239

Epidemiological investigation of a cholera outbreak and its socioeconomic determinants in southwest state, Somalia, January - August, 2024.
Tahlil AA, Adan NM, Abdi HM, Gedi S, Osman MM, Aden SM, Umeokonkwo CD, Mohamed MA, Sultan KM. Confl Health. 2025 Oct 14;19(1):74. doi: 10.1186/s13031-025-00716-7. PMID: 41084059 Free PMC article.

Calreticulin Enhances Therapeutic Immune Responses of Dry Thermostat-Stressed Hepatocellular Carcinoma Cell **Vaccine**.
Zhang D, Fu X, Zhou C, Xing X, Zheng Y, Zhou Y, Zheng X, Chen G, Zou J, Zeng Y, Liu X. ACS Nano. 2025 Oct 13. doi: 10.1021/acsnano.5c07598. Online ahead of print. PMID: 41083934

SARS-CoV-2 vaccination and plasma levels of psychotropic agents: a prospective cohort study.
Ferrea S, Kuzo N, Giupponi G, Messina E, Raponi A, Paulzen M, Hiemke C, Conca A, Schoretsanitis G. Expert Opin Drug Metab Toxicol. 2025 Oct 16:1-6. doi: 10.1080/17425255.2025.2575386. Online ahead of print. PMID: 41083916

Older Adults and Vaccination Status: A Cross-Sectional Analysis of the "ECORSINOS" Study.
da Rosa Lerner E, Mahmud IC, Lenz CA, Ochoa AC, Rodrigues AK, Orsi JP, Schneider RH, Behar PRP, Machado DC. AIDS Behav. 2025 Oct 14. doi: 10.1007/s10461-025-04881-x. Online ahead of print. PMID: 41083660

Trained immunity: induction of an inflammatory memory in disease.
Schlüter T, van Elsas Y, Priem B, Ziogas A, Netea MG. Cell Res. 2025 Oct 14. doi: 10.1038/s41422-025-01171-y. Online ahead of print. PMID: 41083592

Influence of immune history when choosing a SARS-CoV-2 booster strategy.
Larsen SL, Noor I, West H, Chandra E, Martinez PP, Kraay ANM. Sci Rep. 2025 Oct 13;15(1):35640. doi: 10.1038/s41598-025-19659-3. PMID: 41083528 Free PMC article.

Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines.
Pesce M, Feikin DR, Higdon MM, O'Brien KL, Patel MK, Rearte A, Vizzotti C, Wilder-Smith A, Parker EPK. Nat Commun. 2025 Oct 13;16(1):9059. doi: 10.1038/s41467-025-63950-w. PMID: 41083450 Free PMC article.

Pathogenicity analysis and control strategies to combat avian diseases: mechanisms of increased virulence of Marek's disease virus and the development of vaccines against poultry red mites.
Murata S. J Vet Med Sci. 2025 Oct 13. doi: 10.1292/jvms.25-0304. Online ahead of print. PMID: 41083376 Free article.

Effects of government health and immunisation financing on routine childhood vaccination during the COVID-19 pandemic: a difference-in-differences study.
Lee D, Kim TT, Griffiths U, Seidel M, Freitas Attaran M, Lavayen MC, Cabrera-Clerget A. BMJ Open. 2025 Oct 13;15(10):e104188. doi: 10.1136/bmjopen-2025-104188. PMID: 41083294 Free PMC article.

Effectiveness of Recombinant Herpes Zoster **Vaccine** in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster **Vaccine**.
Vielot NA, Jonsson Funk M, Stürmer T, Fix J, Becker-Dreps S, Weber DJ, Lund JL. Ann Intern Med. 2025 Oct 14. doi: 10.7326/ANNALS-24-02409. Online ahead of print. PMID: 41082726

Highly accurate protein structure prediction-based virtual docking pipeline accelerating the identification of anti-schistosomal compounds.
Cheng W, Gu M, Wang Y, Wang J, Li S, Chen G, Chen X, Oyeyemi OT, Hong Y, Hu W, Wang J. PLoS Pathog. 2025 Oct 13;21(10):e1013274. doi: 10.1371/journal.ppat.1013274. eCollection 2025 Oct. PMID: 41082582 Free PMC article.

Social inequalities in **vaccine** coverage and their effects on epidemic spreading.
Manna A, Karsai M, Perra N. PLoS Comput Biol. 2025 Oct 13;21(10):e1013585. doi: 10.1371/journal.pcbi.1013585. eCollection 2025 Oct. PMID: 41082566 Free PMC article.

Social imitation dynamics of vaccination driven by **vaccine** effectiveness and beliefs.
Fu F, Zhuo R, Chen X. PLoS Comput Biol. 2025 Oct 13;21(10):e1013586. doi: 10.1371/journal.pcbi.1013586. eCollection 2025 Oct. PMID: 41082565 Free PMC article.

Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA **vaccine**: A phase 3, randomized, active-controlled study.
Kawamoto A, Hashida M, Ishida K, Furihata K, Ota A, Takahashi K, Sakakibara S, Nakano T, Takeshita F. PLoS Med. 2025 Oct 13;22(10):e1004499. doi: 10.1371/journal.pmed.1004499. eCollection 2025 Oct. PMID: 41082550 Free PMC article.

Is vaccination a feasible public health strategy against fatal Borna disease virus 1 (BoDV-1) encephalitis? An epidemiological perspective.
Pörtner K, Frank C, Wilking H, Stark K, Herden C, Beer M, Rubbenstroth D, Tappe D. PLoS Pathog. 2025 Oct 13;21(10):e1013571. doi: 10.1371/journal.ppat.1013571. eCollection 2025 Oct. PMID: 41082543 Free PMC article.

Correction: Level and determinants of pentavalent **vaccine** dropout during infancy: A hierarchical analysis of community-level longitudinal study.
Bekuma TT, Seme A, Ahmed S, Abera M. PLoS One. 2025 Oct 13;20(10):e0334536. doi: 10.1371/journal.pone.0334536. eCollection 2025. PMID: 41082507 Free PMC article.

Beyond alarmism: what Australia's influenza season really tells us about Italy.
Branda F, Romano C, Ceccarelli G, Scarpa F, Ciccozzi M. Pathog Glob Health. 2025 Oct 13:1-9. doi: 10.1080/20477724.2025.2573304. Online ahead of print. PMID: 41082385

Neurological Adverse Events from COVID-19 Vaccination and It's Associated Factors in Burkina Faso: Analysis of Spontaneous Reports from the National Database of Pharmacovigilance from 2021 to 2023.
Dabilgou AA, Ouedraogo EW, Kyelem JMAW, Dravé A, Wanré O, Napon C, Millogo A. J Neuroimmune Pharmacol. 2025 Oct 13;20(1):89. doi: 10.1007/s11481-025-10249-8. PMID: 41082015

Clostridium chauvoei Antigens: Applications, Available Options and Potential Alternatives in the Future.
Zahmatkesh A. Curr Microbiol. 2025 Oct 13;82(12):551. doi: 10.1007/s00284-025-04554-x. PMID: 41081857

Optimization and scalable production of Corynebacterium diphtheriae toxin using an animal component free medium: a pathway towards safer **vaccine** development.
Chawla PR, Addepally U. Arch Microbiol. 2025 Oct 13;207(11):298. doi: 10.1007/s00203-025-04479-w. PMID: 41081812

The role of dentists in promoting human papillomavirus vaccination for oropharyngeal cancer prevention: A cross-sectional survey of dentists in North Carolina.
Woon J, Boynton MH, Onyeama UF, Vielot NA, Lietzan AD. J Am Dent Assoc. 2025 Oct 13:S0002-8177(25)00541-0. doi: 10.1016/j.adaj.2025.08.018. Online ahead of print. PMID: 41081663

Extracellular matrix-mimicking cryogels in tissue engineering and cancer therapy: from structural design to translational applications abstract.
Liu Y, Li C, Zhu T, Li R, Zhang M, Li X, Cai D, Dai Z, Wan L, Lu H. J Mater Chem B. 2025 Oct 13. doi: 10.1039/d5tb01412c. Online ahead of print. PMID: 41078341

Feed particle size and live-attenuated coccidiosis vaccination interact to improve productive performance rather than significant effects on gastrointestinal tract development and meat quality in broilers.
Bozkurt M, Karazeybek E. Br Poult Sci. 2025 Oct 13:1-14. doi: 10.1080/00071668.2025.2567361. Online ahead of print. PMID: 41078138

Lyophilized Listeria monocytogenes vaccines for storage at non-ultra-low temperatures and cancer therapy.
Paulishak W, Isenhower L, Modaresahmadi S, Hajimirzaei S, Shoultz J, Wood LM. Int J Pharm. 2025 Oct 14;685:126239. doi: 10.1016/j.ijpharm.2025.126239. Online ahead of print. PMID: 41076206

Design and in vivo evaluation of a multi-epitope **vaccine** that suppresses tumour growth in a murine colorectal cancer model.
Khodadadi A, Afshar S, Najafi R, Zamani A, Dalirfardouei R, Soleimani M. J Drug Target. 2025 Oct 15:1-16. doi: 10.1080/1061186X.2025.2573054. Online ahead of print. PMID: 41063694

Monkeypox in South Asia: a systematic review.
Wangdi K, Adhikary R, Liu Z, Vardoulakis S, McFarlane RA, Kotepui M, Hu W, Suwannatrai AT, Tsheten T. Emerg Microbes Infect. 2025 Dec;14(1):2572677. doi: 10.1080/22221751.2025.2572677. Epub 2025 Oct 21. PMID: 41060816

COVID-19 update: 2025-2026 **vaccine** formulations and recommendations.
[No authors listed] Med Lett Drugs Ther. 2025 Oct 13;67(1739):166-168. doi: 10.58347/tml.2025.1739d. PMID: 41060676

Ionizable Lipid Nanoparticles for mRNA Delivery: Internal Self-Assembled Inverse Mesophase Structure and Endosomal Escape.
Yu H, Dyett BP, Drummond CJ, Zhai J. Acc Chem Res. 2025 Oct 21;58(20):3210-3222. doi: 10.1021/acs.accounts.5c00522. Epub 2025 Oct 8. PMID: 41060394

Stapling of β-Glucans Increases Antibody Binding.
Ledvinka J, Kullmann R, Reuber EE, Weikl T, Ricardo MG, Seeberger PH. J Am Chem Soc. 2025 Oct 15;147(41):37634-37640. doi: 10.1021/jacs.5c12690. Epub 2025 Oct 7. PMID: 41054343 Free PMC article.

Extracellular vesicles: Antiviral functions and applications in therapeutics and vaccines.
Gao Q, Zhan Y, Zhang J, Sun D, Xiang H, Bao C, Xu Y, Gao Q, Mao L. iScience. 2025 Sep 10;28(10):113542. doi: 10.1016/j.isci.2025.113542. eCollection 2025 Oct 17. PMID: 41050925 Free PMC article.

Bivalent mRNA **vaccine** booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice.
Linger ME, Jorritsma SHT, Horst JB, Zevenhoven-Dobbe JC, Rijlaarsdam F, Colstrup E, Beijnes M, de Vries JJC, Arens R, Murugan R, Myeni SK; in collaboration with BREAK COVID group. iScience. 2025 Sep 1;28(10):113479. doi: 10.1016/j.isci.2025.113479. eCollection 2025 Oct 17. PMID: 41035684 Free PMC article.

Virus-Like Particle-Based Personalized Neoantigen Nano-**Vaccine** for Tumor Immunotherapy and Recurrence Prevention.
Zhou S, Wang C, Ning Y, Wang Y, Xin F, Ren L, Wang Y. ACS Nano. 2025 Oct 14;19(40):35385-35400. doi: 10.1021/acsnano.5c06278. Epub 2025 Oct 1. PMID: 41032465

A Synthetic Liposome Nanoparticle **Vaccine** Platform for Broad-Spectrum **Vaccine** Design.
Zhang M, Gao Z, Feng S, Wang X, Wang H, Yang C, Lin X, Xu Z, Zhang N, Li Y, Tian H, Jin N, Yu B, Wang P, Li C, Yu X. Nano Lett. 2025 Oct 15;25(41):14832-14842. doi: 10.1021/acs.nanolett.5c03021. Epub 2025 Oct 1. PMID: 41032408

Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2.
Singh ON, Berry U, Joshi G, Asuru TR, Chandrasekar K, Narayanan S, Srivastava P, Tiwari M, Chattopadhyay S, Mehdi F, Panda BN, Nayak D, Mani S, Shrivastava T, Batra G, Ranjith-Kumar CT, Guchhait P, Surjit M. iScience. 2025 Sep 4;28(10):113498. doi: 10.1016/j.isci.2025.113498. eCollection 2025 Oct 17. PMID: 41031374 Free PMC article.

Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2+1 schedule.
Mt-Isa S, Chumbley JR, Kelly MS, Weaver J, Banniettis N. Expert Rev Vaccines. 2025 Dec;24(1):946-957. doi: 10.1080/14760584.2025.2569037. Epub 2025 Oct 14. PMID: 41026657 Free article.

Multi-epitope transplantation enables cross-type neutralization of phylogenetically distant HPV11/6/53 in mice.
Qian C, Xu Y, Huang Y, Chen J, Jiang Y, Shen J, Gao F, Ren T, Lu Y, Zhang S, Zhang C, Wang D, Zhou L, Li T, Kong Z, Zheng Q, Yu H, Gu Y, Xia N, Li S. iScience. 2025 Sep 2;28(10):113477. doi: 10.1016/j.isci.2025.113477. eCollection 2025 Oct 17. PMID: 41019378 Free PMC article.

Does Medical Training of Local Health Department Executives Improve COVID-19 Vaccination Uptake and Case Growth?
Hou X, Jiao Y, Chen ZA, Fang X, Khan MM. J Public Health Manag Pract. 2025 Nov-Dec 01;31(6):E441-E450. doi: 10.1097/PHH.0000000000002208. Epub 2025 Oct 21. PMID: 40971522

GLP-1 Drugs in Heart Failure, beta-Blockers After MI, the Shingles **Vaccine**, and More From ESC 2025.
Abbasi J. JAMA. 2025 Oct 21;334(15):1315-1317. doi: 10.1001/jama.2025.15515. PMID: 40971173

In Vitro and *Ex Vivo* evidence that pharmacological induction of the hypoxia response pathway efficiently restricts measles and Nipah virus infections.
Canus L, Jacquemin C, Orch WE, Ogire E, Ferren M, Moissonnier E, Lalande A, Bourgeais A, Ducret G, Bouget J, Haftek Z, Jacolin F, Aublin-Gex A, Décimo D, Moroso M, Mely S, Rozières A, Faure M, Diaz O, Gerlier D, Si-Tahar M, Lotteau V, Perrin-Cocon L, Mathieu C, Vidalain PO. Emerg Microbes Infect. 2025 Dec;14(1):2563067. doi: 10.1080/22221751.2025.2563067. Epub 2025 Oct 18. PMID: 40958637 Free PMC article.

Efficacy of a glycoprotein G-deficient infectious laryngotracheitis virus **vaccine** delivered in the drinking-water.
Gopakumar G, Coppo MJC, Hartley CA, Underwood G, Diaz-Méndez A, Devlin JM. Avian Pathol. 2025 Oct 20:1-9. doi: 10.1080/03079457.2025.2559873. Online ahead of print. PMID: 40952354 Free article.

Real-world effectiveness and safety of nirsevimab, RSV maternal **vaccine** and RSV vaccines for older adults: a living systematic review and meta-analysis.
Lee B, Trusinska D, Ferdous S, Pei R, Kwok HHY, Schwarze J, Williams TC, Gibbons C, Quint JK, Sheikh A, Drysdale SB, Shi T. Thorax. 2025 Oct 15;80(11):838-848. doi: 10.1136/thorax-2025-223376. PMID: 40930981 Free article.

Cell death pathways in response to *Mycobacterium tuberculosis* and other mycobacterial infections.
Faysal MA, Hanafy M, Zinniel DK, Tanni FY, Muthukrishnan E, Rathnaiah G, Barletta RG. Infect Immun. 2025 Oct 14;93(10):e0040125. doi: 10.1128/iai.00401-25. Epub 2025 Sep 9. PMID: 40924403 Free PMC article.

Evaluation of Mycoplasma mycoides subsp. mycoides antigens capable of stimulating host IRG-47 release identifies Mmm604, Mmm605, and Mmm606 as potential subunit **vaccine** antigens.
Liu T, Zhao H, Wu Q, Wei Y, Xin J, Pan Q. Infect Immun. 2025 Oct 14;93(10):e0018625. doi: 10.1128/iai.00186-25. Epub 2025 Sep 9. PMID: 40924390 Free PMC article.

Influenza and COVID-19 Multicomponent **Vaccine** in Adults-Reply.
Rudman Spergel AK, Callendret B, Kostanyan L. JAMA. 2025 Oct 14;334(14):1301-1302. doi: 10.1001/jama.2025.12225. PMID: 40920411

Influenza and COVID-19 Multicomponent **Vaccine** in Adults.
Liu Z, Zhang L, Jiang M. JAMA. 2025 Oct 14;334(14):1301. doi: 10.1001/jama.2025.12222. PMID: 40920372

Listeria monocytogenes adenosine auxotrophs are impaired for intracellular and extracellular growth but retain potent immunogenicity.
Feng Y, Lobanovska M, Vickery J, Castillo JG, Güereca L, Chang SK, DuPage M, Portnoy DA. Infect Immun. 2025 Oct 14;93(10):e0034325. doi: 10.1128/iai.00343-25. Epub 2025 Sep 5. PMID: 40910949 Free PMC article.

Good governance essential to expanding **vaccine** capacity and strengthening public trust.
Lee K, Kohler J. Lancet. 2025 Oct 18;406(10513):1707-1710. doi: 10.1016/S0140-6736(25)01681-2. Epub 2025 Aug 29. PMID: 40889510

Precision Vaccinology: Making Vaccines Work Better for Women and Men.
Scully EP, Morgan R, Klein SL. J Infect Dis. 2025 Oct 15;232(4):756-759. doi: 10.1093/infdis/jiaf397. PMID: 40833848

An intranasal quadruple variant **vaccine** approach using SARS-CoV-2 and influenza A: Delta, Omicron, H1N1and H3N2.
Singh R, Gulani M, Vijayanand S, Arte T, Adediran E, Pasupuleti D, Patel P, Ferguson A, Uddin M, Zughaier SM, D'souza MJ. Int J Pharm. 2025 Oct 15;683:126043. doi: 10.1016/j.ijpharm.2025.126043. Epub 2025 Aug 6. PMID: 40759221 Free article.

Design of soluble Notch agonists that drive T cell development and boost immunity.
Mout R, Jing R, Tanaka-Yano M, Egan ED, Eisenach H, Kononov MA, Windisch R, Najia MAT, Tompkins A, Hensch L, Bingham T, Gunage R, Zhao Y, Edman NI, Li C, Wang D, Schlaeger TM, Zon LI, North TE, Lendahl U, Rowe RG, Baker D, Blacklow SC, Daley GQ. Cell. 2025 Oct 16;188(21):5980-5994.e28. doi: 10.1016/j.cell.2025.07.009. Epub 2025 Aug 1. PMID: 40752493

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.
Samandari T, Achola M, Hutter JN, Mboya G, Otieno W, Kee JJ, Huang Y, Aponte JJ, Ockenhouse CF, Lee CK, Polakowski L, Yacovone M, Tapley A, Dadabhai S, Mkhize NN, Kaldine H, Bhebhe S, Moore PL, Hural J, Garrett N, Kublin JG. J Infect Dis. 2025 Oct 15;232(4):e565-e570. doi: 10.1093/infdis/jiaf398. PMID: 40751436 Free PMC article.

Impact of skin model and dissolvable microneedle design on efficiency of cutaneous protein delivery.
Moore LE, van Hulst IA, van der Maaden K, Vucen S, Moore AC. Int J Pharm. 2025 Oct 15;683:126022. doi: 10.1016/j.ijpharm.2025.126022. Epub 2025 Jul 30. PMID: 40750046 Free article.

SARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post **vaccine**.
Saxena S, Zhirova A, Krishnan R, Healy B, Sanon E, Gopalakrishnan N, Solberg A, Conway S, Chitnis T. J Neuroimmunol. 2025 Oct 15;407:578694. doi: 10.1016/j.jneuroim.2025.578694. Epub 2025 Jul 25. PMID: 40749532

Mass spectrometric analysis of lipid-linked oligosaccharide heterogeneity in genetically modified E. coli used for glycoconjugate bacterial **vaccine** production.
Palubeckaite I, Moran AB, Cramer DAT, Torrente-López A, Smits WK, Weerdenburg E, Al Kaabi A, Beurret M, Anish C, Wuhrer M, Nicolardi S. Carbohydr Polym. 2025 Oct 15;366:123928. doi: 10.1016/j.carbpol.2025.123928. Epub 2025 Jun 19. PMID: 40733845 Free article.

Association of a Novel IgG3 Allele With Malaria in Children From the Sepik Region of Papua New Guinea.
Saeed M, Aitken EH, Naung MT, Bourke C, Wu KW, Longley RJ, Chung AW, Damelang T, Kiniboro B, Mueller I, Rogerson SJ. J Infect Dis. 2025 Oct 15;232(4):e555-e564. doi: 10.1093/infdis/jiaf390. PMID: 40717585 Free PMC article.

Syphilis Pathogenesis: Host Immune Response vs Pathogen Immune Evasion.
Liu A, Giacani L, Tuero I, Klausner JD. J Infect Dis. 2025 Oct 15;232(4):760-766. doi: 10.1093/infdis/jiaf388. PMID: 40708500 Free PMC article.

Effectiveness of COVID-19 **vaccine** boosters for reducing COVID-19 mortality among people aged 65 years or older, Australia, August 2023 - February 2024: a retrospective observational cohort study.
Liu B, Scaria A, Stepien S, Macartney K. Med J Aust. 2025 Oct 20;223(8):418-422. doi: 10.5694/mja2.70015. Epub 2025 Jul 24. PMID: 40703004 Free PMC article.

Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines.
King LM, Andrejko KL, Kobayashi M, Xing W, Cohen AL, Self WH, Resser JJ, Whitney CG, Baughman A, Kio M, Grijalva CG, Traenkner J, Rouphael N, Lewnard JA. J Infect Dis. 2025 Oct 15;232(4):e609-e620. doi: 10.1093/infdis/jiaf376. PMID: 40692487 Free PMC article.

Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study.
Swiderski M, Lewis S, Vinogradova Y, Ridd MJ, Yiu ZZN, Lloyd-Lavery A, Prasad V, Gran S. Br J Dermatol. 2025 Oct 17;193(5):889-897. doi: 10.1093/bjd/ljaf237. PMID: 40577787

Discovery and SAR exploration of novel nanomolar 3,4-dihydroquinazolin-2(1H)-one non-nucleoside reverse transcriptase inhibitors.
Goffin E, Torfs L, Tsingis F, Švestka D, Erven K, Uyttersprot K, Heens C, Wilms S, Rozenski J, Lescrinier E, Pannecouque C, Verwilst P. Eur J Med Chem. 2025 Oct 15;296:117818. doi: 10.1016/j.ejmech.2025.117818. Epub 2025 May 29. PMID: 40554307

Difficult-to-treat recurrent pericarditis after SARS-CoV-2 vaccination.
Marchetta M, Lopez RI, Golino M, Thomas G, Abbate A. Int J Cardiol. 2025 Oct 15;437:133516. doi: 10.1016/j.ijcard.2025.133516. Epub 2025 Jun 14. PMID: 40523563

Herpes Zoster **Vaccine** and Cardiovascular Disease Risk.
Lai SW, Liao KF. J Infect Dis. 2025 Oct 15;232(4):e706. doi: 10.1093/infdis/jiaf229. PMID: 40304454

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 **Vaccine**.
Atmar RL, Lyke KE, Posavad CM, Deming ME, Brady RC, Dobrzynski D, Edupuganti S, Mulligan MJ, Rupp RE, Rostad CA, Jackson LA, Martin JM, Shriver MC, Rajakumar K, Coler RN, El Sahly HM, Kottkamp AC, Branche AR, Frenck RW, Johnston C, Babu TM, Bäcker M, Archer JI, Crandon S, Nakamura A, Nayak SU, Szydlo D, Dominguez Islas CP, Brown ER, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Beigel JH, Pasetti M, Roberts PC. J Infect Dis. 2025 Oct 15;232(4):971-981. doi: 10.1093/infdis/jiaf176. PMID: 40298376 Free PMC article.

Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024.
Lewis NM, Harker EJ, Cleary S, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Halasa NB, Lauring AS, Martin ET, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Duggal A, Felzer JR, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Ferguson SAN, Mosier J, Qadir N, Chang SY, Ginde AA, Zepeski A, Mallow C, Harris ES, Johnson NJ, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Surie D, Dawood FS, Ellington S, Self WH. J Infect Dis. 2025 Oct 15;232(4):e626-e636. doi: 10.1093/infdis/jiaf185. PMID: 40198276

A Miniaturized Assay to Evaluate Plasmodium cynomolgi and Plasmodium knowlesi as Models for Prioritizing Plasmodium vivax **Vaccine** Targets.
Dass S, Kundu P, Naskar D, Kanjee U, Ferreira MU, Rayner JC, Duraisingh MT. J Infect Dis. 2025 Oct 15;232(4):912-917. doi: 10.1093/infdis/jiaf136. PMID: 40083318

Epidemiology of Invasive Haemophilus influenzae Type a Disease in Alaska, 2018-2022.
Burket TL, Scobie HM, DeByle C, Bressler S, Blake I, Orell L, Massay S, Bruden D, Westley BP, McLaughlin JB, Fischer M. J Infect Dis. 2025 Oct 15;232(4):e585-e588. doi: 10.1093/infdis/jiaf132. PMID: 40071574

Rift Valley Fever Virus Infectivity in Milk Stored at a Wide Range of Temperatures.
Dawes BE, De La Mota-Peynado A, Rezende IM, Buyukcangaz EK, Harvey AM, Gerken KN, Winter CA, Bayrau B, Mitzel DN, Waggoner JJ, Pinsky BA, Wilson WC, LaBeaud AD. J Infect Dis. 2025 Oct 15;232(4):e661-e670. doi: 10.1093/infdis/jiaf060. PMID: 39928032

Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies.
Chandrasekaran P, Berry IM, Callier V, Anthony SM, Hensley K, Kuhn JH, Shaw-Saliba K, Kennedy SB, Kieh M, Browne SM, Crozier I, Davey RT, Lane HC, Hensley LE, Follmann DA. J Infect Dis. 2025 Oct 15;232(4):1004-1014. doi: 10.1093/infdis/jiae632. PMID: 39718991 Free PMC article.

Patentes registradas en Patentscope

Estrategia de búqueda: *(Vaccine) AND DP:([13.10.2025 TO 21.10.2025])* 33 *records.*

1.WO/2025/214210NOVEL HUMAN SYNCYTIAL VIRUS RSV B MRNA VACCINE
WO - 16.10.2025
Int.Class C12N 15/113 Appl.No PCT/CN2025/086546 Applicant NEXTRANSLATE BIOPHARMACEUTICAL (HANGZHOU) CO., LTD. Inventor ZHAN, Xiaoyan
Provided are a recombinant human syncytial virus RSV B pre F mRNA, a human syncytial virus vaccine prepared from the mRNA, and a use thereof. A recombinant human syncytial virus mRNA is obtained by screening and modifying a virus strain and performing mRNA sequence optimization and a human syncytial virus mRNA/LNP nanoparticle vaccine is further successfully obtained. Mice immunized with the prepared vaccine can generate a specific antibody and a neutralizing antibody, and protection duration testing of the vaccine indicated that the human syncytial virus vaccine can provide an immune protection period of one year or more. After virus infection, a booster vaccine is given, so that the content of the antibody is greatly increased, suggesting that the human syncytial virus vaccine has a very good virus protection effect. A cotton rat lung experiment had demonstrated that the vaccine can effectively control the amplification of RSV viruses in lung, and has an immune effect significantly superior to that of the same class of commercially available similar syncytial virus vaccine products.

2.20250320315BLETILLA STRIATA POLYSACCHARIDE, PREPARATION METHOD AND USE THEREOF, IMMUNE ADJUVANT AND NANO VACCINE CONTAINING THE SAME
US - 16.10.2025
Int.Class C08B 37/00 Appl.No 17423635 Applicant KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES Inventor Jiangmiao HU

Disclosed is a *Bletilla striata* polysaccharide, its preparation method and use, an immune adjuvant and a nano vaccine containing the *Bletilla striata* polysaccharide. The *Bletilla striata* polysaccharide of the disclosure has the immunomodulatory effect. The *Bletilla striata* polysaccharide and the protein vaccine are self-assembled to generate the nano vaccine after mixing, and the self-assembled nano vaccine is relatively uniform round particles. When the nano vaccine is used to immunize mice, it is able to activate antigen presenting cells (APCs) and improve their uptake of antigen. The nano vaccine enables mice to generate antibody and cell response which are 2-10 times stronger than that of the traditional vaccines.

3.4630051VACCINE FOR VACCINATING A CANINE
EP - 15.10.2025
Int.Class A61K 39/235 Appl.No 23817780 Applicant INTERVET INT BV Inventor PEARCE JACQUELINE

The present invention relates to a vaccine for use in a method of inducing an immune response in a canine against infectious canine hepatitis and/or infectious tracheobronchitis. To combine a convenient way of administering the vaccine and a good protection against ICH and infectious tracheobronchitis, the vaccine is a first vaccine comprising a canine adenovirus type 2, and the method comprises - administration of an immunologically effective dose of the first vaccine, - subcutaneous administration of an immunologically effective dose of a second vaccine comprising a canine adenovirus type 2 7-42 days after the first vaccine, and - oral administration of an immunologically effective dose of a third vaccine comprising a canine adenovirus type 2 10-14 months after the first vaccine.

4.WO/2025/214372INFLUENZA MRNA VACCINE AND PREPARATION METHOD THEREFOR
WO - 16.10.2025
Int.Class C12N 15/62 Appl.No PCT/CN2025/087875 Applicant CANSINO (SHANGHAI) BIOLOGICAL RESEARCH CO., LTD. Inventor LI, Jin
The present invention relates to an influenza virus mRNA vaccine, wherein the mRNA vaccine encodes a fusion protein containing an influenza virus hemagglutinin protein (HA) or a functional fragment thereof and an Fc or a variant thereof. The mRNA vaccine can improve the immunogenicity of an influenza virus HA antigen and the titer of a functional antibody by means of expressing the fusion protein containing the influenza hemagglutinin protein (HA) and the Fc or the variant thereof. The influenza virus mRNA vaccine prepared in the present invention can induce the body to generate a high-level and long-acting immune response at a low dose, thereby enabling a reduction in the clinical administration dose.

5.WO/2025/216559PORCINE CIRCOVIRUS INFECTION-PREVENTING VACCINE COMPOSITION EFFECTIVE AGAINST PCV2B AND PCV2D
WO - 16.10.2025
Int.Class A61K 39/12 Appl.No PCT/KR2025/004841 Applicant INNOVAC INC. Inventor HAHN, Tae-Wook
The present invention relates to a porcine circovirus infection-preventing vaccine composition in which the amount of an antigen is adjusted. The vaccine composition according to the present invention has been verified to be safe, and, unlike existing patents, has also been identified to effectively induce protective immunity against PCV2d challenge vaccination in pigs (SPF minipigs) which are target animals. In addition, it has been identified that animals inoculated with the vaccine composition of the present invention have significantly reduced PCV2-related lesions. As such, effective protection against currently prevalent porcine circovirus is indicated, and thus the present invention can be widely utilized in the fields of porcine circovirus infection prevention and pig farming.

6.20250319170Veterinary Vaccine Composition Against Parasitic Worms, Method for Treating and Preventing Infection by Parasitic Worms, and Use
US - 16.10.2025
Int.Class A61K 39/00 Appl.No 18574262 Applicant FABP BIOTECH DESENVOLVIMENTO EM BIOTECNOLOGIA LTDA Inventor Miriam Tendler

The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein (rSm14) or homologous proteins of Fasciola hepatica (FhFABPs) that provide a homogeneous, long-term immune response against parasitic worms. The invention is also intended to provide a method for treating and preventing infection caused by parasitic worms, in particular *Fasciola hepatica,* and also the use of these proteins in a vaccine composition against parasitic worms.

7.20250319172ANTICANCER VACCINE COMPOSITION COMPRISING HSP90 ANTIGENIC PEPTIDE AND USE THEREOF
US - 16.10.2025
Int.Class A61K 39/00 Appl.No 18697210 Applicant ASTON SCI. INC. Inventor Jin Ho KANG

The present disclosure relates to an anticancer vaccine composition including a peptide of SEQ ID NO: 1 and a peptide of SEQ ID NO: 2, which are epitopes of HSP90, and the vaccine composition according to the present disclosure may effectively inhibit the growth of tumors in an animal model of tumor cell line transplantation without severe adverse effects, and thus may be useful for treating cancer or preventing cancer recurrence.

8.20250320255UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES
US - 16.10.2025
Int.Class C07K 14/005 Appl.No 18869181 Applicant Design-Zyme LLC Inventor Peter Petillo

Self-adjuvanting vaccine compositions comprising at least one modified immunogen via in vitro glycosylation methods that provide a rational approach for generating glycosylated versions of immunogens via the reducing end of a linear carbohydrate, the reducing end containing an N-acyl-2-amino moiety. Self-adjuvanting vaccine compositions comprising a plurality of heterologous immunogens associated with a multivalent carrier, wherein at least one immunogen is glycosylated to allow for mucosal delivery. Self-adjuvanting vaccine compositions comprising multivalent carriers and related methods using the self-adjuvanting vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection. Pathogens for which this approach may be useful include, but are not limited to, influenza viruses, rhinoviruses, human immunodeficiency viruses (HIV), respiratory syncytial virus (RSV), coronaviruses, *Babesia, Borrelia, Neisseria*, and *Chlamydia*, and the related diseases thereof.

9.WO/2025/217373VACCINE FOR HUMAN PAPILLOMAVIRUS AND USE THEREOF
WO - 16.10.2025
Int.Class C12N 15/62 Appl.No PCT/US2025/024023 Applicant CHANG, Yung-nien Inventor CHANG, Yung-nien
The present disclosure provides a vaccine for human papillomavirus (HPV) and use thereof for treating a subject with human papillomavirus-associated diseases. The vaccine may include a nucleotide having a fusion gene. The fusion gene may include an optimized DNA subsequence having an HPV-I8 E6 expressing gene set forth in SEQ ID NO: 4, or an mRNA subsequence transcribed from the optimized DNA subsequence.

10.WO/2025/216911SELECTING A CANDIDATE ANTIGEN FOR A VACCINE USING A BIOLOGICAL RESPONSE MACHINE LEARNING MODEL
WO - 16.10.2025
Int.Class G16B 40/20 Appl.No PCT/US2025/022354 Applicant SANOFI PASTEUR, INC. Inventor DAVIDSON, Philip
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for selecting a candidate antigen for inclusion in a vaccine using a biological response machine learning model. In one aspect, a method comprises obtaining data comprising a set of immunization histories and a set of viral strains, generating a plurality of predicted biological response scores using a biological response machine learning model, and selecting a candidate antigen for inclusion in a vaccine based at least in part on the plurality of predicted biological response scores.

11.4630048METHODS AND COMPOSITIONS FOR VACCINATING PIGLETS AGAINST PRRS-1 VIRUS
EP - 15.10.2025
Int.Class A61K 39/12 Appl.No 23837499 Applicant ZOETIS SERVICES LLC Inventor BALASCH SANUY MONICA

This disclosure provides a vaccine comprising a modified live PRRS-1 virus attenuated in cells expressing porcine CD163 for use in inducing protective immunity in a piglet that is older than 60 hours of age, wherein said vaccine is administered to said piglet intranasally.

12.20250319178Cancer Vaccines and Methods of Treatment Using The Same
US - 16.10.2025
Int.Class A61K 39/39 Appl.No 19248819 Applicant Inovio Pharmaceuticals, Inc. Inventor Jian Yan

The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.

13.4630562NUCLEIC ACID BASED CANCER VACCINE AND METHODS THEREOF
EP - 15.10.2025
Int.Class C12N 15/62 Appl.No 23901720 Applicant ADVANCED RNA VACCINE ARV TECH INC Inventor ZHU HUABIN

Described herein are composition and methods of using thereof. The compositions described herein can include a single chain trimer nucleic acid encoding a first T cell epitope, a β2-microglobulin, and a MHC class I heavy chain sequence. The methods described herein can be used to activate and/or expand an antigen-presenting cell. The methods described herein can also be used to treat or prevent a viral infection, bacterial infection, parasitic infection and/or a cancer in a subject.

14.20250319132Methods and compositions for improving the immune response against viral pathogens
US - 16.10.2025
Int.Class A61K 35/17 Appl.No 19180751 Applicant Mirror Biologics, Inc. Inventor Michael Har-Noy

Immunotherapy regimens against a viral pathogen in individuals are disclosed. The immunotherapy regimen is a universal vaccine that is administered intradermally. Multiple intradermal doses of the universal vaccine are administered to elderly individuals to prime the individual's immune system for an effective response against a viral pathogen.

15.WO/2025/216910SELECTING A CANDIDATE ANTIGEN FOR A VACCINE USING A BIOLOGICAL RESPONSE MACHINE LEARNING MODEL
WO - 16.10.2025
Int.Class G16B 20/20 Appl.No PCT/US2025/022331 Applicant SANOFI PASTEUR, INC. Inventor DAVIDSON, Philip
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for selecting a candidate antigen for inclusion in a vaccine using a biological response machine learning model. In one aspect, a method comprises receiving immunization history data for a subject, receiving viral strain data, using a biological response machine learning model to generate a predicted biological response score characterizing a predicted biological response of the subject having the immunization history to being exposed to the viral strain, and outputting the predicted biological response score.

16.20250319175VACCINATION WITH REPLICON PARTICLES AND OIL ADJUVANT
US - 16.10.2025
Int.Class A61K 39/193 Appl.No 19040767 Applicant INTERVET INC. Inventor Mark A. MOGLER

The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and oil adjuvants. To a vaccine, and a kit of parts comprising the replicon particles and the oil adjuvant. Also to methods and uses of making and using the vaccine and the components of the kit.

17.WO/2025/217575FELINE INFECTIOUS PERITONITIS MRNA VACCINE
WO - 16.10.2025

Int.Class A61K 39/12 Appl.No PCT/US2025/024358 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor BROSTOFF, Terza
In vitro-transcribed (IVT) RNA molecules and uses thereof as a feline infectious peritonitis(FIP) vaccine are described. An example IVT RNA molecule comprises a polynucleotide encoding a Feline Coronavirus (FCoV) nucleocapsid protein antigen, which is optionally loaded in a Lipid Nanoparticle (LNP) formulation and capable of being expressed in vivo.

18.4631970NUCLEIC ACID MOLECULES AND USES THEREOF
EP - 15.10.2025
Int.Class C07K 14/005 Appl.No 25194681 Applicant CUREVAC SE Inventor RAUCH SUSANNE
The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

19.20250319060METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19
US - 16.10.2025
Int.Class A61K 31/357 Appl.No 19037137 Applicant Lloyd Hung Loi Tran Inventor Lloyd Hung Loi Tran

The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

20.20250319177RNA COMPOSITIONS FOR DELIVERY OF MONKEYPOX ANTIGENS AND RELATED METHODS
US - 16.10.2025
Int.Class A61K 39/275 Appl.No 18869125 Applicant BioNTech SE Inventor Asaf Poran

The present disclosure provides pharmaceutical compositions for delivery of monkeypox antigens (e.g., a monkeypox vaccine) and related technologies (e.g., components thereof and/or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more monkeypox antigens or fragments thereof.

21.4631527NANOPARTICLE COMPRISING PEPTIDE-BASED CONJUGATE FOR DELIVERING MRNA INTO B CELL AND T CELL AND USES THEREOF
EP - 15.10.2025
Int.Class A61K 48/00 Appl.No 23901151 Applicant SEOUL NAT UNIV R&DB FOUNDATION Inventor PARK YOON JEONG

The present invention relates to a peptide-based conjugate for mRNA delivery, which overcomes the limitations of existing lipid nanoparticles and is capable of safely and immediately responding to new variants of infectious diseases. mRNA binds to an RNA-binding peptide of the conjugate and undergoes self-assembly by an amphipathic polypeptide or polymer to thereby form a peptide and mRNA complex nanoparticle. The nanoparticle and a pharmaceutical composition comprising same were confirmed to efficiently increase intracellular delivery of mRNA and exhibit a vaccine effect by mRNA.

22.20250322927MODELS FOR PREDICTING MUTANT P53 FITNESS AND THEIR IMPLICATIONS IN CANCER THERAPY
US - 16.10.2025
Int.Class G16H 20/17 Appl.No 18546762 Applicant Memorial Sloan-Kettering Cancer Center Inventor Benjamin GREENBAUM

The present technology relates to methods, computing devices, and systems for predicting the fitness of mutant p53 based on the loss of transcription factor function and immunogenicity of a particular TP53 mutation. The fitness of mutant p53 may be used to determine whether a patient will benefit from a particular anti-cancer therapy such as immune checkpoint inhibitor therapy, adoptive T-cell therapy, or prophylactic cancer vaccine therapy.

23.4630027COMPOSITE AIDS VACCINE GENERATING ANTI-HIV SPECIFIC NEUTRALIZING ANTIBODIES AND/OR ANTI-HIV CYTOTOXIC T CELLS
EP - 15.10.2025
Int.Class A61K 38/00 Appl.No 23821605 Applicant DYS IMMUNE THERAPEUTICS Inventor ZAGURY DANIEL

In the present invention, the Applicant provides a novel method for prophylactically or curatively treating acquired immune deficiency syndrome (AIDS) in a subject in need thereof, wherein said subject is a human immunodeficiency virus (HIV)-seropositive patient. The Applicant also provides a novel method for preventing acquired immune deficiency syndrome (AIDS) in a subject in need thereof, wherein said subject is a human immunodeficiency virus (HIV)-seronegative patient. The Applicant further provides a novel method for prophylactically treating or curatively treating acquired immune deficiency syndrome (AIDS) in a subject in need thereof, wherein said subject is a human immunodeficiency virus (HIV)-seropositive Elite Controller patient.

24.4630047VACCINE AGAINST KLEBSIELLA PNEUMONIAE
EP - 15.10.2025
Int.Class A61K 39/108 Appl.No 23820856 Applicant IDORSIA PHARMACEUTICALS LTD Inventor BROECKER FELIX

The present invention relates to novel immunogenic compounds comprising at least one antigen of Formula (I), in particular immunogenic compounds of Formula (II), and their use as pharmaceuticals, in particular as vaccines. The invention also concerns related aspects including intermediates, as well as processes for the preparation of the immunogenic compounds. Furthermore, the invention relates to pharmaceutical compositions comprising the immunogenic compounds, as well as the use of the antigen of Formula (I) in biological assays.

25.20250319035CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR
US - 16.10.2025

Int.Class A61K 9/51 Appl.No 18861755 Applicant Shuwen TONG Inventor Shuwen TONG

A nucleic acid-loaded calcium-containing cationic lipid nanoparticle, comprising a cationic lipid, a neutral lipid, a PEGylated lipid, and cholesterol and/or a cholesterol ester. The cationic lipid nanoparticle can be used for preparing a gene-based drug for local injection into the body or a nucleic acid vaccine for local or systemic injection into the body.

26.20250319159INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPY
US - 16.10.2025
Int.Class A61K 38/20 Appl.No 19028024 Applicant IO BIOTECH APS Inventor Mads Hald ANDERSEN

The invention relates to the field of prophylaxis and therapy of cancer. Provided is a Indoleamine 2,3-dioxygenase (IDO) or peptide fragments hereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived herefrom or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. The invention also provides that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. The invention further provides the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.

27.WO/2025/214886HETEROBIFUNCTIONAL LINKER
WO - 16.10.2025
Int.Class A61K 47/69 Appl.No PCT/EP2025/059229 Applicant ETH ZURICH Inventor BODE, Jeffrey
The present invention relates to a heterobifunctional linker and its use in the preparation of a vaccine.

28.4631526HETEROBIFUNCTIONAL LINKER
EP - 15.10.2025
Int.Class A61K 47/69 Appl.No 24168910 Applicant ETH ZUERICH Inventor BODE JEFFREY
The present invention relates to a heterobifunctional linker and its use in the preparation of a vaccine.

29.20250320466DUCK-DERIVED RNA POLYMERASE I PROMOTER AND RECOMBINANT VECTOR CARRYING SAME
US - 16.10.2025
Int.Class C12N 7/00 Appl.No 18866156 Applicant REPUBLIC OF KOREA(ANIMAL AND PLANT QUARANTINE AGENCY) Inventor Yu-Na LEE

The present disclosure relates to a duck-derived RNA polymerase I promoter and a recombinant vector comprising the same. The use of the duck-derived RNA polymerase I promoter of the present disclosure enables the production of avian influenza viruses with high efficiency. Furthermore, In the event of the emergence of the variant and novel avian influenza viruses, vaccine candidate libraries and diagnostic standards can be early ensured on the basis of the virus production system, thereby minimizing damage to poultry industry.

30.2025242201HIV VACCINE IMMUNOGENS
AU - 16.10.2025
Int.Class Appl.No 2025242201 Applicant California Institute of Technology Inventor BJORKMAN, Pamela J.

31.WO/2025/215320CHARACTERISATION OF ANTIGENIC/IMMUNOGENIC PEPTIDES FOR THE DEVELOPMENT OF CONTRACEPTIVE VACCINES FOR THE PURPOSE OF LIMITING THE PROLIFERATION OF THE RODENT ARVICOLA TERRESTRIS SCHERMAN
WO - 16.10.2025
Int.Class A61K 39/00 Appl.No PCT/FR2025/050280 Applicant UNIVERSITE CLERMONT AUVERGNE Inventor DREVET, Joël
The present invention relates to the definition of a pool of antigenic sperm peptides with high species specificity for regulating populations of water vole (Arvicola terrestris scherman) using a vaccine approach.

32.20250320281METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
US - 16.10.2025
Int.Class C07K 16/10 Appl.No 19031993 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE, INC. Inventor Po-Ying Chan-Hui

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

33.20250319176PIV5-BASED COVID-19 VACCINE
US - 16.10.2025
Int.Class A61K 39/215 Appl.No 18026943 Applicant UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. Inventor Biao He

The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) protein for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20251013"<=20251021 22 records*

Document ID	Title	Inventor	Applicant Name
US 12447205 B2	Vaccine molecules	Grødeland; Gunnveig et al.	University of Oslo
US 12447202 B2	Arthrospira platensis oral vaccine delivery platform	Roberts; James et al.	LUMEN BIOSCIENCE, INC.
US 12448417 B2	Cryptosporidiosis vaccine	Van Roosmalen; Markus Hendrikus et al.	Intervet Inc.
US 12447127 B2	Thermostable vaccine compositions and methods of preparing the same	Hassett; Kimberly et al.	The Regents of the University of Colorado, a body corporate
US 12448437 B2	Transplant tolerance induction with carbodiimide treated tolerizing vaccine	Hering; Bernhard J. et al.	Regents of the University of Minnesota
US 12448416 B2	Stabilized coronavirus spike (s) protein immunogens and related vaccines	He; Linling et al.	The Scripps Research Institute
US 12447206 B2	Nanoparticle vaccines with novel structural components	He; Linling et al.	The Scripps Research Institute
US 12447204 B2	Prime-boost influenza vaccine	Muster; Thomas	VIVALDI BIOSCIENCES INC.
US 20250319178 A1	Cancer Vaccines and Methods of Treatment Using The Same	Yan; Jian	Inovio Pharmaceuticals, Inc.
US 20250319176 A1	PIV5-BASED COVID-19 VACCINE	He; Biao	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
US 20250319172 A1	ANTICANCER VACCINE COMPOSITION COMPRISING HSP90 ANTIGENIC PEPTIDE AND USE THEREOF	KANG; Jin Ho et al.	ASTON SCI. INC.,CHA VACCINE RESEARCH INSTITUTE CO., LTD

US 20250320315 A1	BLETILLA STRIATA POLYSACCHARIDE, PREPARATION METHOD AND USE THEREOF, IMMUNE ADJUVANT AND NANO VACCINE CONTAINING THE SAME	HU; Jiangmiao et al.	KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES,INSTITUTE OF MEDICAL BIOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES
US 20250319170 A1	Veterinary Vaccine Composition Against Parasitic Worms, Method for Treating and Preventing Infection by Parasitic Worms, and Use	Tendler; Miriam et al.	FABP BIOTECH DESENVOLVIMENTO EM BIOTECNOLOGIA LTDA,FUNDAÇÃO OSWALDO CRUZ
US 20250320255 A1	UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES	Petillo; Peter et al.	Design-Zyme LLC
US 12440555 B2	Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species	Fujisawa; Ayumi et al.	CEVA SANTE ANIMALE
US 12440560 B2	Substituted pyrimidines as vaccine adjuvants	Kimura; Hidenori et al.	Sumitomo Pharma Co., Ltd.
US 12442018 B2	Recombinant cytomegalovirus vectors as vaccines for tuberculosis	Evans; Thomas G. et al.	International AIDS Vaccine Inititative, Inc.,Oregon Health and Science University
US 12441989 B2	Serum-free medium for avian vaccine production and uses thereof	Hughes; William Troy	BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
US 12440551 B2	tFIBER protein fragment of avian egg drop syndrome virus and vaccine composition prepared thereof, preparation method and use	Tian; Kegong et al.	PULIKE BIOLOGICAL ENGINEERING, INC.
US 12440556 B2	Genetically modified cell line for production of Marek's disease virus vaccine and methods of making and using the same	Ameiss; Keith Allen et al.	Zoetis Services LLC
US 12440553 B2	Multivalent carriers and related vaccine compositions	Cohen; Alexander A. et al.	California Institute of Technology

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES